NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2017
(Unaudited)
1. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (“GAAP”) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.
The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the year ended
December 31, 2016
, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the Securities and Exchange Commission (“SEC”) on March 1, 2017. The Condensed Consolidated Balance Sheet at
December 31, 2016
, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.
There have been no new or material changes to the significant accounting policies discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, that are of significance, or potential significance to the Company.
Adopted Accounting Pronouncements
In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09,
Improvements to Employee Share-Based Payment Accounting
, intended to improve the accounting for share-based payment transactions as part of its simplification initiative. The ASU requires entities to record all excess tax benefits and tax deficiencies as an income tax benefit or expense in the statement of income. The recognition of excess tax benefits and deficiencies and changes to diluted earnings per share are to be applied prospectively. For tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable, the Company recorded a
$7.7 million
cumulative-effect adjustment in retained earnings as of the beginning of 2017, the year of adoption. The Company applied the presentation changes for excess tax benefits from financing activities to operating activities in the statement of cash flows using a prospective transition method. The guidance allows for an election to recognize forfeitures as they occur rather than on an estimated basis. The Company will continue to account for forfeitures on an estimated basis. During the period ended March 31, 2017, there were no excess tax benefits recognized in the Consolidated Statement of Income and classified as an operating activity in the Condensed Consolidated Statement of Cash Flows.
In January 2017, the FASB issued ASU No. 2017-01,
Clarifying the Definition of a Business
, included in ASC Topic 805,
Business Combinations
, which revises the definition of a business. The revised definition clarifies that outputs must be the result of inputs and substantive processes that provide goods or services to customers, other revenue, or investment income. The guidance will be effective for the Company's annual and interim reporting periods beginning January 1, 2018, and early adoption is permitted. The Company adopted the new definition of a business during the first quarter of 2017, and it did not have a material impact on its business practices, financial condition, results of operations, or disclosures.
Recently Issued Accounting Pronouncements
In May 2014, the FASB issued ASU No. 2014-09,
Revenue from Contracts with Customers
. The new standard can be applied either retrospectively to each prior reporting period presented (i.e., full retrospective adoption) or with the cumulative effect of initially applying the update recognized at the date of the initial application (i.e., modified retrospective adoption) along with additional disclosures. This new standard will replace most of the existing revenue recognition guidance in GAAP when it becomes effective. The new standard, as amended, becomes effective for the Company in the first quarter of fiscal year 2018, but allows the Company to adopt the standard one year earlier if it so chooses. The Company currently anticipates adopting this standard using the full retrospective method to restate each prior period presented. The Company is evaluating the timing and the impact of adopting this standard to its Condensed Consolidated Financial Statements.
In February 2016, the FASB issued ASU No. 2016-02,
Leases
, which seeks to increase transparency and comparability among organizations by, among other things, recognizing lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous GAAP and disclosing key information about leasing arrangements. ASU No. 2016-02 becomes effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the provisions of ASU No. 2016-02 and assessing the impact, if any, it may have on the Company’s Condensed Consolidated Financial Statements.
In June 2016, the FASB issued ASU No. 2016-13,
Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments
. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating ASU 2016-13 and assessing the impact, if any, it may have to the Company’s consolidated results of operations, financial position and cash flows.
In August 2016, the FASB issued ASU No. 2016-15,
Classification of Certain Cash Receipts and Cash Payments
. The new standard provides for specific guidance how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating ASU 2016-15 and assessing the impact, if any, it may have to the Company’s Condensed Consolidated Statement of Cash Flows.
In October 2016, the FASB issued ASU No. 2016-16,
Intra-Entity Transfers of Assets Other Than Inventory
, which requires companies to account for the income tax effects of intercompany sales and transfers of assets other than inventory in the period in which the transfer occurs. The new standard is effective for public business entities for annual periods beginning after December 15, 2017 (i.e. 2018 for a calendar-year entity). Early adoption is permitted for all entities as of the beginning of an annual period. The guidance is to be applied using a modified retrospective approach with a cumulative catch-up adjustment to opening retained earnings in the period of adoption. The Company is currently analyzing the impact of ASU No. 2016-16 on the Company’s Condensed Consolidated Financial Statements.
In November 2016, the FASB issued ASU No. 2016-18,
Restricted Cash
, which requires entities to show the changes in total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions on the balance sheet. The reconciliation can either be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard is effective for public business entities for fiscal years beginning after December 15, 2017 and interim periods therein and is to be applied retrospectively. Early adoption is permitted. The Company is currently analyzing the impact of ASU No. 2016-18 on the Company’s Condensed Consolidated Financial Statements.
2. Net Income per Share
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
March 31,
|
Net Income per Basic and Diluted Share:
|
|
2017
|
|
2016
|
(in thousands except per share amounts)
|
|
|
|
|
Numerator
|
|
|
|
|
Income attributable to PDL’s shareholders used to compute net income per basic and diluted share
|
|
$
|
7,241
|
|
|
$
|
55,887
|
|
|
|
|
|
|
Denominator
|
|
|
|
|
|
|
Total weighted average shares used to compute net income attributable to PDL’s shareholders, per basic share
|
|
163,745
|
|
|
163,701
|
|
Restricted stock outstanding
|
|
247
|
|
|
134
|
|
Shares used to compute net income attributable to PDL’s shareholders, per diluted share
|
|
163,992
|
|
|
163,835
|
|
|
|
|
|
|
Net income attributable to PDL’s shareholders per share - basic
|
|
$
|
0.04
|
|
|
$
|
0.34
|
|
Net income attributable to PDL’s shareholders per share - diluted
|
|
$
|
0.04
|
|
|
$
|
0.34
|
|
The Company computes net income per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net income per diluted share include shares that may be issued pursuant to outstanding stock options and restricted stock awards, the 4.0% Convertible Senior Notes due February 1, 2018 (the “February 2018 Notes”) and the 2.75% Convertible Senior Notes due December 1, 2021 (the “December 2021 Notes”), in each case, on a weighted average basis for the period that the notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if converted method.
February 2018 Notes Purchased Call Option and Warrant Potential Dilution
The Company excluded from its calculation of net income per diluted share
12.2 million
and
23.8 million
shares for the
three
months ended
March 31, 2017
and 2016, respectively, for warrants issued in February 2014, because the exercise price of the warrants exceeded the volume-weighted average share price (“VWAP”) of the Company’s common stock and conversion of the underlying February 2018 Notes is not assumed, therefore no stock would be issuable upon conversion; however, these securities could be dilutive in future periods. The purchased call options issued in February 2014 will always be anti-dilutive; therefore
13.8 million
and
26.9 million
shares were excluded from the calculation of net income per diluted share for the
three
months ended
March 31, 2017
and 2016, respectively, and were excluded from the calculation of net income per diluted share. For information related to the conversion rates on the Company’s convertible debt, see Note 12.
December 2021 Notes Capped Call Potential Dilution
In November 2016, the Company issued
$150.0 million
in aggregate principal of the December 2021 Notes, which provide in certain situations for the conversion of the outstanding principal amount of the December 2021 Notes into shares of the Company’s common stock at a predefined conversion rate. See Note 12, “Convertible Notes and Term Loans”, for additional information. In conjunction with the issuance of the December 2021 Notes, the Company entered into a capped call transaction with a hedge counterparty. The capped call transaction is expected generally to reduce the potential dilution, and/or offset, to an extent, the cash payments the Company may choose to make in excess of the principal amount, upon conversion of the December 2021 Notes. The Company has excluded the capped call transaction from the diluted EPS computation as such securities would have an antidilutive effect and those securities should be considered separately rather than in the aggregate in determining whether their effect on diluted EPS would be dilutive or antidilutive. For additional information regarding the capped call transaction related to the Company’s December 2021 Notes, see Note 12.
Anti-Dilutive Effect of Restricted Stock Awards
For the three months ended
March 31, 2017
and
2016
, the Company excluded approximately
1,719,000
and
1,039,000
shares underlying restricted stock awards, respectively, calculated on a weighted average basis, from its net income per diluted share calculations because their effect was anti-dilutive.
3. Fair Value Measurements
The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:
Level 1 – based on quoted market prices in active markets for identical assets and liabilities;
Level 2 – based on quoted market prices for similar assets and liabilities, using observable market-based inputs or unobservable market-based inputs corroborated by market data; and
Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.
The following tables present the fair value of the Company’s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2017
|
|
December 31, 2016
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds
|
|
$
|
45
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
45
|
|
|
$
|
4
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
4
|
|
Certificates of deposit
|
|
—
|
|
|
75,000
|
|
|
—
|
|
|
75,000
|
|
|
—
|
|
|
75,000
|
|
|
—
|
|
|
75,000
|
|
Commercial paper
|
|
—
|
|
|
19,991
|
|
|
—
|
|
|
19,991
|
|
|
—
|
|
|
19,987
|
|
|
—
|
|
|
19,987
|
|
Warrants
|
|
—
|
|
|
178
|
|
|
—
|
|
|
178
|
|
|
—
|
|
|
78
|
|
|
—
|
|
|
78
|
|
Royalty rights - at fair value
|
|
—
|
|
|
—
|
|
|
293,801
|
|
|
293,801
|
|
|
—
|
|
|
—
|
|
|
402,318
|
|
|
402,318
|
|
Total
|
|
$
|
45
|
|
|
$
|
95,169
|
|
|
$
|
293,801
|
|
|
$
|
389,015
|
|
|
$
|
4
|
|
|
$
|
95,065
|
|
|
$
|
402,318
|
|
|
$
|
497,387
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anniversary payment
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
88,493
|
|
|
$
|
88,493
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
88,001
|
|
|
$
|
88,001
|
|
Contingent consideration
|
|
—
|
|
|
—
|
|
|
43,600
|
|
|
43,600
|
|
|
—
|
|
|
—
|
|
|
42,650
|
|
|
42,650
|
|
Total
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
132,093
|
|
|
$
|
132,093
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
130,651
|
|
|
$
|
130,651
|
|
As of March 31, 2017, the Company held
$75.0 million
in a short-term certificate of deposit, which is designated as cash collateral for the letter of credit issued with respect to the first anniversary payment under the Noden Purchase Agreement. There have been
no
transfers between levels during the three-month periods ended
March 31, 2017
and December 31,
2016
. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.
Certificates of Deposit
The fair value of the certificates of deposit is determined using quoted market prices for similar instruments and non-binding market prices that are corroborated by observable market data.
Commercial Paper
Commercial paper securities consist primarily of U.S. corporate debt holdings. The fair value of commercial paper securities is estimated using recently executed transactions or market quoted prices, where observable. Independent pricing sources are also used for valuation.
Warrants
Warrants consist primarily of purchased call options to buy U.S. corporate equity holdings and derivative assets acquired as part of note receivable investments. The fair value of the warrants is estimated using recently quoted market prices or estimated fair value of the underlying equity security and the Black-Scholes option pricing model.
Royalty Rights - At Fair Value
Depomed Royalty Agreement
On October 18, 2013, the Company entered into the Royalty Purchase and Sale Agreement (the “Depomed Royalty Agreement”) with Depomed, Inc. and Depo DR Sub, LLC (together, “Depomed”), whereby the Company acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a
$240.5 million
cash payment. Total consideration was
$241.3 million
, which was comprised of the
$240.5 million
cash payment to Depomed and
$0.8 million
in transaction costs.
The rights acquired include Depomed’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus, Inc. (“Santarus”) (which was subsequently acquired by Salix Pharmaceuticals, Inc. (“Salix), which itself was acquired by Valeant Pharmaceuticals International, Inc. (“Valeant”)) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck & Co., Inc. with respect to sales of Janumet
®
XR (sitagliptin and
metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica N.V. with respect to potential future development milestones and sales of its recently approved fixed-dose combination of Invokana
®
(canagliflozin) and extended-release metformin tablets, marketed as Invokamet XR
®
; (d) from Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed’s license agreement with Boehringer Ingelheim, including its recently approved product, Jentadueto XR
®
; and (e) from LG Life Sciences and Valeant for sales of extended-release metformin tablets in Korea and Canada, respectively.
Under the terms of the Depomed Royalty Agreement, the Company receives all royalty and milestone payments due under license agreements between Depomed and its licensees until the Company has received payments equal to two times the cash payment it made to Depomed, after which all net payments received by Depomed will be shared evenly between the Company and Depomed.
The Depomed Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.
As of
March 31, 2017
, and December 31,
2016
, the Company determined that its royalty purchase interest in Depo DR Sub represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Depo DR Sub that most significantly impact Depo DR Sub’s economic performance and is not the primary beneficiary of Depo DR Sub; therefore, Depo DR Sub is not subject to consolidation by the Company.
The financial asset acquired represents a single unit of accounting. The fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. This financial asset is classified as a Level 3 asset within the fair value hierarchy, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies. The discounted cash flows are based upon expected royalties from sales of licensed products over a nine-year period. The discount rates utilized range from approximately
15%
to
25%
. Significant judgment is required in selecting appropriate discount rates. At
March 31, 2017
, an evaluation was performed to assess those rates and general market conditions potentially affecting the fair market value.
Should these discount rates increase or decrease by 2.5%, the fair value of the asset could decrease by $12.2 million or increase by $13.9 million, respectively. A third-party expert was engaged to help management develop its original estimate of the expected future cash flows. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $4.0 million, respectively.
When the Company acquired the Depomed royalty rights, Glumetza was marketed by Santarus. In January 2014, Salix acquired Santarus and assumed responsibility for commercializing Glumetza, which was generally perceived to be a positive development because of Salix’s larger sales force and track record in the successful commercialization of therapies. In late 2014, Salix made a number of disclosures relating to an excess of supply at the distribution level of Glumetza and other drugs that it commercialized and the practices leading to this excess of supply which were under review by Salix’s audit committee in relation to the related accounting practices. Because of these disclosures and the Company’s lack of direct access to information as to the levels of inventory of Glumetza in the distribution channels, the Company commenced a review of all public statements by Salix, publicly available historical third-party prescription data, analyst reports and other relevant data sources. The Company also engaged a third-party expert to specifically assess estimated inventory levels of Glumetza in the distribution channel and to ascertain the potential effects those inventory levels may have on expected future cash flows. Salix was acquired by Valeant in early April 2015. In mid-2015, Valeant implemented two price increases on Glumetza. At year-end 2015, a third-party expert was engaged by the Company to assess the impact of the Glumetza price adjustments and near-term market entrance of generic equivalents to the expected future cash flows. Based on the analysis performed, management revised the underlying assumptions used in the discounted cash flow analysis at year-end 2015. In February and August of 2016, a total of three generic equivalents to Glumetza entered the market. At December 31, 2016, management re-evaluated, with assistance of a third-party expert, the erosion of market share data, the gross-to-net revenue adjustment assumptions and Glumetza demand data. These data and assumptions are based on available but limited information. The Company’s expected future cash flows as of March 31, 2017 have been adjusted based on the demand and supply data of Glumetza.
As of March 31, 2017, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date. The Company continues to monitor whether the generic competition further affects sales of Glumetza and thus royalties on such sales paid to the Company. Due to the uncertainty around Valeant’s marketing and
pricing strategy, as well as the recent generic competition and limited historical demand data after generic market entrance, the Company may need to further reduce future cash flows in the event of more rapid reduction in market share of Glumetza or a further erosion in net pricing. In January 2016, the Company exercised its audit right under the Depomed Royalty Agreement with respect to the Glumetza royalties. The information initially provided by Valeant to the independent auditors engaged to perform the royalty audit was substantially incomplete, and the Company has since identified the information necessary to complete the audit to Valeant and is awaiting the provision of the necessary and missing information.
On May 31, 2016, the Company obtained a notification indicating that the FDA approved Jentadueto XR for use in patients with Type 2 diabetes. In June 2016, the Company received a
$6.0 million
FDA approval milestone. The product approval was earlier than initially expected. Based on the FDA approval and anticipated timing of the product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model at June 30, 2016. At December 31, 2016, management re-evaluated, with assistance of a third-party expert, the cash flow assumptions for Jentadueto XR and revised the discounted cash flow model. As of March 31, 2017, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.
On September 21, 2016, the Company obtained a notification indicating that the FDA approved Invokamet XR for use in patients with Type 2 diabetes. The product approval triggered a
$5.0 million
approval milestone payment to the Company. Based on the FDA approval and timing of the product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model at March 31, 2017.
On December 13, 2016, the Company obtained a notification indicating that the FDA approved Synjardy XR for use in patients with Type 2 diabetes. The product approval triggered a
$6.0 million
approval milestone payment to the Company. Based on the FDA approval and expected product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model at March 31, 2017. In April 2017, Boehringer Ingelheim launched Synjardy XR.
As of
March 31, 2017
, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was
$161.6 million
and the maximum loss exposure was
$161.6 million
.
VB Royalty Agreement
On June 26, 2014, the Company entered into a Royalty Purchase and Sale Agreement (the “VB Royalty Agreement”) with Viscogliosi Brothers, LLC (“VB”), whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA, in exchange for a
$15.5 million
cash payment, less fees.
The royalty rights acquired includes royalties accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company receives all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to 2.3 times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB may repurchase the royalty right at any time on or before June 26, 2018, for a specified amount. The chief executive officer of Paradigm Spine is one of the owners of VB. The Paradigm Spine Credit Agreement and the VB Royalty Agreement were negotiated separately.
The fair value of the royalty right at
March 31, 2017
, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a nine-year period. The discount rate utilized was approximately
17.5%
. Significant judgment is required in selecting the appropriate discount rate.
Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.2 million or increase by $1.4 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.4 million, respectively.
A third-party expert was engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value.
As of
March 31, 2017
, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was
$15.2 million
and the maximum loss exposure was
$15.2 million
.
U-M Royalty Agreement
On November 6, 2014, the Company acquired a portion of all royalty payments of the Regents of the University of Michigan’s (“U-M”) worldwide royalty interest in Cerdelga (eliglustat) for
$65.6 million
pursuant to the Royalty Purchase and Sale Agreement with U-M (the “U-M Royalty Agreement”). Under the terms of the U-M Royalty Agreement, the Company will receive
75%
of all royalty payments due under U-M’s license agreement with Genzyme Corporation, a Sanofi company (“Genzyme”) until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States on August 19, 2014, in the European Union on January 22, 2015, and in Japan in March 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities. While marketing applications have been approved in the European Union and Japan, national pricing and reimbursement decisions are delayed in some countries. At June 30, 2016, a third-party expert was engaged by the Company to assess the impact of the delayed pricing and reimbursement decisions to Cerdelga’s expected future cash flows. Based on the analysis performed, management revised the underlying assumptions used in the discounted cash flow analysis at period end.
The fair value of the royalty right at
March 31, 2017
was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a six-year period. The discount rate utilized was approximately
12.8%
. Significant judgment is required in selecting the appropriate discount rate.
Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $2.3 million or increase by $2.5 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.9 million, respectively.
A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.
As of
March 31, 2017
, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was
$35.7 million
and the maximum loss exposure was
$35.7 million
.
ARIAD Royalty Agreement
On July 28, 2015, the Company entered into the revenue interest assignment agreement (the “ARIAD Royalty Agreement”) with ARIAD Pharmaceuticals, Inc. (“ARIAD”), whereby the Company acquired the rights to receive royalties from ARIAD’s net revenues generated by the sale, distribution or other use of Iclusig
®
(ponatinib), a cancer medicine for the treatment of adult patients with chronic myeloid leukemia, in exchange for up to
$200.0 million
in cash payments. The purchase price of
$100.0 million
was payable in two tranches of
$50.0 million
each, with the first tranche having been funded on July 28, 2015 and the second tranche having been funded on July 28, 2016. Upon the occurrence of certain events, including a change of control of ARIAD, the Company had the right to require ARIAD to repurchase the royalty rights for a specified amount. The Company elected the fair value option to account for the hybrid instrument in its entirety. Any embedded derivative shall not be separated from the host contract. The asset acquired pursuant to the ARIAD Royalty Agreement represents a single unit of accounting.
In January 2017, Takeda Pharmaceutical Company Limited (“Takeda”) announced that it had entered into a definitive agreement to acquire ARIAD. The acquisition was consummated on February, 16, 2017 and the Company exercised its put option on the same day, which resulted in an obligation by Takeda to pay the Company a 1.2x multiple of the
$100.0 million
funded by the Company under the ARIAD Royalty Agreement, less royalty payments already received by the Company.
On March 30, 2017, Takeda fulfilled its obligations under the put option and paid the Company the repurchase price of
$108.2 million
for the royalty rights under the ARIAD Royalty Agreement.
AcelRx Royalty Agreement
On September 18, 2015, the Company entered into a royalty interest assignment agreement (the “AcelRx Royalty Agreement”) with ARPI LLC, a wholly owned subsidiary of AcelRx Pharmaceuticals, Inc. (“AcelRx”), whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso
®
(sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx’s commercial partner, Grünenthal, in exchange for a
$65.0 million
cash payment. Under the terms of the AcelRx Royalty Agreement, the Company will receive
75%
of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx’s license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and
(ii) the expiration of the licensed patents. Zalviso received marketing approval by the European Commission in September 2015. Grünenthal launched Zalviso in the second quarter of 2016 and the Company started to receive royalties in the third quarter of 2016.
As of
March 31, 2017
, and December 31,
2016
, the Company determined that its royalty rights under the AcelRx Royalty Agreement represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC’s economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.
The fair value of the royalty right at
March 31, 2017
was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a fourteen-year period. The discount rate utilized was approximately
13.4%
. Significant judgment is required in selecting the appropriate discount rate.
Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $10.2 million or increase by $12.8 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $1.7 million, respectively
. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. At each reporting period, an evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.
As of
March 31, 2017
, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was
$69.6 million
and the maximum loss exposure was
$69.6 million
.
Dr. Stephen Hoffman is the President of 10x Capital, Inc., a third-party consultant to the Company, and is also a member of the board of directors of AcelRx. Dr. Hoffman recused himself from the AcelRx board of directors with respect to the entirety of its discussions and considerations of the transaction. Dr. Hoffman was compensated for his contribution to consummate this transaction by the Company as part of his consulting agreement with the Company. The Company concluded Dr. Hoffman is not considered a related party in accordance with FASB Accounting Standard Codification (“ASC”) 850,
Related Party Disclosures
and SEC Regulation S-X,
Related Party Transactions Which Affect the Financial Statements
.
Avinger Credit and Royalty Agreement
On April 18, 2013, the Company entered into the Credit Agreement (the “Avinger Credit and Royalty Agreement”) with Avinger, Inc. (“Avinger”), under which the Company made available to Avinger up to
$40.0 million
(of which only
$20.0 million
was funded) to be used by Avinger in connection with the commercialization of its lumivascular catheter devices and the development of Avinger’s lumivascular atherectomy device. On September 22, 2015, Avinger elected to prepay the note receivable in whole (including interest and a prepayment fee) for a payment of
$21.4 million
in cash.
Under the terms of the Avinger Credit and Royalty Agreement, the Company was entitled to receive royalties at a rate of
1.8%
on Avinger’s net revenues until the note receivable was repaid by Avinger. Upon the repayment of the note receivable by Avinger, which occurred on September 22, 2015, the royalty rate was reduced to
0.9%
, subject to certain minimum payments from the prepayment date until April 2018. The Company has accounted for the royalty rights in accordance with the fair value option. The fair value of the royalty right at
March 31, 2017
was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a one-year period. The discount rate utilized was approximately
15.0%
.
Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $41,000 or increase by $44,000, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase or decrease by $35,000, respectively.
Management considered the contractual minimum payments when developing its estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.
As of
March 31, 2017
, the fair value of the royalty asset as reported in the Company’s Condensed Consolidated Balance Sheet was
$1.4 million
and the maximum loss exposure was
$1.4 million
.
Kybella Royalty Agreement
On July 8, 2016, the Company entered into a royalty purchase and sales agreement with an individual, whereby the Company acquired that individual’s rights to receive certain royalties on sales of KYBELLA
®
by Allergan, in exchange for a
$9.5 million
cash payment and up to
$1.0 million
in future milestone payments based upon product sales targets. The Company started to receive royalty payments during the third quarter of 2016.
The fair value of the royalty right at
March 31, 2017
, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of a licensed product over a nine-year period. The discount rate utilized was approximately
14.4%
. Significant judgment is required in selecting the appropriate discount rate.
Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.0 million or increase by $1.2 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $258,000, respectively
. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. At each reporting period, an evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.
As of
March 31, 2017
, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheets was
$10.3 million
and the maximum loss exposure was
$10.3 million
.
The following tables summarize the changes in Level 3 assets and liabilities and the gains and losses included in earnings for the
three months ended
March 31, 2017
:
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
|
|
|
|
|
|
|
|
(in thousands)
|
|
Royalty Rights -
At Fair Value
|
Fair value as of December 31, 2016
|
|
|
|
$
|
402,318
|
|
|
|
|
|
|
|
|
|
Financial instruments settled
|
|
|
|
(108,169
|
)
|
|
Total net change in fair for the period
|
|
|
|
|
|
|
Change in fair value of royalty rights - at fair value
|
|
$
|
13,146
|
|
|
|
|
|
Proceeds from royalty rights - at fair value
|
|
$
|
(13,494
|
)
|
|
|
|
|
Total net change in fair value for the period
|
|
|
|
(348
|
)
|
|
|
|
|
|
|
|
Fair value as of March 31, 2017
|
|
|
|
|
$
|
293,801
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value as of
|
|
Change of
|
|
Royalty Rights -
|
|
Fair Value as of
|
(in thousands)
|
|
December 31, 2016
|
|
Ownership
|
|
Change in Fair Value
|
|
March 31, 2017
|
Depomed
|
|
$
|
164,070
|
|
|
$
|
—
|
|
|
$
|
(2,432
|
)
|
|
$
|
161,638
|
|
VB
|
|
14,997
|
|
|
—
|
|
|
174
|
|
|
15,171
|
|
U-M
|
|
35,386
|
|
|
—
|
|
|
299
|
|
|
35,685
|
|
ARIAD
|
|
108,631
|
|
|
(108,169
|
)
|
|
(462
|
)
|
|
—
|
|
AcelRx
|
|
67,483
|
|
|
—
|
|
|
2,113
|
|
|
69,596
|
|
Avinger
|
|
1,638
|
|
|
—
|
|
|
(248
|
)
|
|
1,390
|
|
KYBELLA
|
|
10,113
|
|
|
—
|
|
|
208
|
|
|
10,321
|
|
|
|
$
|
402,318
|
|
|
$
|
(108,169
|
)
|
|
$
|
(348
|
)
|
|
$
|
293,801
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities
|
|
|
|
|
|
(in thousands)
|
|
Anniversary Payment
|
|
Contingent Consideration
|
Fair value as of December 31, 2016
|
|
$
|
(88,001
|
)
|
|
$
|
(42,650
|
)
|
|
|
|
|
|
|
|
|
Total net change in fair for the period
|
|
(492
|
)
|
|
(950
|
)
|
|
|
|
|
|
|
|
Fair value as of March 31, 2017
|
|
$
|
(88,493
|
)
|
|
$
|
(43,600
|
)
|
The fair value of the contingent consideration was determined using an income approach derived from the Noden Products revenue estimates and a probability assessment with respect to the likelihood of achieving (a) the level of net sales or (b) generic product launch that would trigger the milestone payments. The key assumptions in determining the fair value are the discount rate and the probability assigned to the potential milestones being achieved. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Condensed Consolidated Statements of Income. The change in fair value of the contingent consideration during the period ending
March 31, 2017
is due primarily to the passage of time, as there have been no significant changes in the key assumptions used in the fair value calculation during the current period.
Gains and losses from changes in Level 3 assets included in earnings for each period are presented in “Royalty rights - change in fair value” and gains and losses from changes in Level 3 liabilities included in earnings for each period are presented in “Change in fair value of anniversary payment and contingent consideration” as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
March 31,
|
(in thousands)
|
|
2017
|
|
2016
|
|
|
|
|
|
Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period
|
|
$
|
13,146
|
|
|
$
|
(27,102
|
)
|
|
|
|
|
|
Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period
|
|
$
|
(1,442
|
)
|
|
$
|
—
|
|
The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2017
|
|
December 31, 2016
|
|
|
Carrying Value
|
|
Fair Value
Level 2
|
|
Fair Value
Level 3
|
|
Carrying Value
|
|
Fair Value
Level 2
|
|
Fair Value
Level 3
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Wellstat Diagnostics note receivable
|
|
$
|
50,191
|
|
|
$
|
—
|
|
|
$
|
51,397
|
|
|
$
|
50,191
|
|
|
$
|
—
|
|
|
$
|
52,260
|
|
Hyperion note receivable
|
|
1,200
|
|
|
—
|
|
|
1,200
|
|
|
1,200
|
|
|
—
|
|
|
1,200
|
|
LENSAR note receivable
|
|
43,909
|
|
|
—
|
|
|
43,900
|
|
|
43,909
|
|
|
—
|
|
|
43,900
|
|
Direct Flow Medical note receivable
(1)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
10,000
|
|
|
—
|
|
|
10,000
|
|
kaléo note receivable
|
|
146,670
|
|
|
—
|
|
|
143,511
|
|
|
146,685
|
|
|
—
|
|
|
142,539
|
|
CareView note receivable
|
|
19,055
|
|
|
—
|
|
|
20,035
|
|
|
18,965
|
|
|
—
|
|
|
19,200
|
|
Total
|
|
$
|
261,025
|
|
|
$
|
—
|
|
|
$
|
260,043
|
|
|
$
|
270,950
|
|
|
$
|
—
|
|
|
$
|
269,099
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
February 2018 Notes
|
|
$
|
122,692
|
|
|
$
|
123,918
|
|
|
$
|
—
|
|
|
$
|
121,595
|
|
|
$
|
123,918
|
|
|
$
|
—
|
|
December 2021 Notes
|
|
112,426
|
|
|
132,096
|
|
|
—
|
|
|
110,848
|
|
|
122,063
|
|
|
—
|
|
Total
|
|
$
|
235,118
|
|
|
$
|
256,014
|
|
|
$
|
—
|
|
|
$
|
232,443
|
|
|
$
|
245,981
|
|
|
$
|
—
|
|
(1)
As a result of the foreclosure proceedings, the Company obtained ownership of most of the Direct Flow Medical assets through the Company’s wholly-owned subsidiary, DFM, LLC. Those assets are held for sale and carried at the lower of carrying amount or fair value, less estimated selling cost, as of March 31, 2017. For a further discussions on this topics, see Note 7.
As of
March 31, 2017
and
December 31, 2016
, the estimated fair values of the kaléo, Inc. note receivable, Hyperion Catalysis International, Inc. note receivable, LENSAR, Inc. note receivable and CareView Communications Inc. note receivable were determined using one or more discounted cash flow models, incorporating expected payments and the interest rate extended on the notes receivable, with fixed interest rates and incorporating expected payments for notes receivable with a variable rate of return.
When deemed necessary, the Company engages a third-party valuation expert to assist in evaluating its investments and the related inputs needed to estimate the fair value of certain investments. The Company determined its notes receivable assets are Level 3 assets as the Company’s valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values and required yield. To provide support for the estimated fair value measurements, the Company considered forward-looking performance related to the investment and current measures associated with high yield indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in similar sectors.
The Wellstat Diagnostics note receivable is secured by substantially all assets and equity interests in Wellstat Diagnostics. In addition, the note is subject to a guaranty from the Wellstat Diagnostics Guarantors. The Direct Flow Medical note receivable and LENSAR, Inc. note receivable are secured by substantially all assets in the respective companies. The estimated fair value of the collateral assets was determined by using an asset approach and discounted cash flow model related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.
On
March 31, 2017
, the carrying values of several of the Company’s notes receivable differed from their estimated fair value. This is the result of discount rates used when performing a discounted cash flow for fair value valuation purposes. The Company determined these notes receivable to be Level 3 assets, as its valuations utilized significant unobservable inputs, estimates of future revenues, expectations about settlement and required yield. To provide support for the fair value measurements, the Company considered forward-looking performance, and current measures associated with high yield and published indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in a similar sector.
The fair values of the Company’s convertible notes were determined using quoted market pricing or dealer quotes.
The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:
|
|
|
|
|
|
|
|
|
|
Asset
|
|
Valuation
Technique
|
|
Unobservable
Input
|
|
March 31, 2017
|
|
December 31,
2016
|
|
|
|
|
|
|
|
|
|
Wellstat Diagnostics
|
|
|
|
|
|
|
|
|
Intellectual Property
|
|
Income Approach
|
|
|
|
|
|
|
|
|
|
|
Discount rate
|
|
13%
|
|
13%
|
|
|
|
|
Royalty amount
|
|
$55-74 million
|
|
$54-74 million
|
Real Estate Property
|
|
Market Approach
|
|
|
|
|
|
|
|
|
|
|
Annual appreciation rate
|
|
4%
|
|
4%
|
|
|
|
|
Estimated realtor fee
|
|
6%
|
|
6%
|
|
|
|
|
Estimated disposal date
|
|
12/31/2017
|
|
12/31/2017
|
Direct Flow Medical
|
|
|
|
|
|
|
|
|
All Assets
|
|
Income Approach
|
|
|
|
|
|
|
|
|
|
|
Discount rate
|
|
N/A
|
|
27%
|
|
|
|
|
Implied revenue multiple
|
|
N/A
|
|
6.9
|
LENSAR
|
|
|
|
|
|
|
|
|
All Assets
|
|
Income Approach
|
|
|
|
|
|
|
|
|
|
|
Discount rate
|
|
15.5%
|
|
25%
|
|
|
|
|
Implied revenue multiple
|
|
1.5-3.0
|
|
2.5
|
At March 31, 2017, the Company had three notes receivable investments on non-accrual status with a cumulative investment cost and fair value of approximately
$95.3 million
and
$96.5 million
, respectively, compared to four note receivable investments on non-accrual status at December 31, 2016 with a cumulative investment cost and fair value of approximately
$105.3 million
and
$107.4 million
, respectively. For the quarters ended March 31, 2017 and 2016, the Company did not recognize any interest for note receivable investments on non-accrual status. During the three months ended March 31, 2017 and 2016, the Company did not recognize losses on extinguishment of notes receivable.
4. Cash, Cash Equivalents and Short-term Investments
As of
March 31, 2017
, and
December 31, 2016
, the Company had invested its excess cash balances primarily in money market funds, and a corporate equity security. The Company’s securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in “Accumulated other comprehensive income” in stockholders’ equity, net of estimated taxes. See Note 3 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, the Company has not experienced credit losses on investments in these instruments, and it does not require collateral for its investment activities.
The following tables summarize the Company’s cash and available-for-sale securities’ amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category reported as cash and cash equivalents, or short-term investments as of
March 31, 2017
, and December 31, 2016:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reported as:
|
|
|
Amortized Cost
|
|
Estimated Fair Value
|
|
Cash and Cash Equivalents
|
|
Short-Term Investments
|
(In thousands)
|
|
|
|
|
|
|
|
|
March 31, 2017
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
314,282
|
|
|
$
|
314,282
|
|
|
$
|
314,282
|
|
|
$
|
—
|
|
Money market funds
|
|
45
|
|
|
45
|
|
|
45
|
|
|
—
|
|
Commercial paper
|
|
19,991
|
|
|
19,991
|
|
|
—
|
|
|
19,991
|
|
Total
|
|
$
|
334,318
|
|
|
$
|
334,318
|
|
|
$
|
314,327
|
|
|
$
|
19,991
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
147,150
|
|
|
$
|
147,150
|
|
|
$
|
147,150
|
|
|
$
|
—
|
|
Money market funds
|
|
4
|
|
|
4
|
|
|
4
|
|
|
—
|
|
Commercial paper
|
|
19,987
|
|
|
19,987
|
|
|
—
|
|
|
19,987
|
|
Total
|
|
$
|
167,141
|
|
|
$
|
167,141
|
|
|
$
|
147,154
|
|
|
$
|
19,987
|
|
5. Concentration of Credit Risk
Customer Concentration
The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues, was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
Licensee
|
|
Product Name
|
|
2017
|
|
2016
|
Genentech
|
|
Avastin
|
|
—
|
%
|
|
38
|
%
|
|
|
Herceptin
|
|
—
|
%
|
|
38
|
%
|
|
|
Xolair
|
|
—
|
%
|
|
13
|
%
|
|
|
|
|
|
|
|
Biogen
|
|
Tysabri
®
|
|
31
|
%
|
|
14
|
%
|
|
|
|
|
|
|
|
Depomed
|
|
Glumetza, Janumet XR, Jentadueto XR and Invokamet XR
|
|
14
|
%
|
|
N/M
|
|
|
|
|
|
|
|
|
N/M
|
|
Tekturna, Tekturna HCT, Rasilez and Rasilez HCT
|
|
28
|
%
|
|
—
|
%
|
|
|
|
|
|
|
|
kaléo
|
|
Interest revenues
|
|
10
|
%
|
|
5
|
%
|
____________________
N/M = Not meaningful
6. Foreign Currency Hedging
The Company designates the foreign currency exchange contracts used to hedge its royalty revenues based on underlying Euro-denominated sales as cash flow hedges. Euro forward contracts are presented on a net basis on the Company’s Condensed Consolidated Balance Sheets as it has entered into a netting arrangement with the counterparty. All Euro forward contracts were classified as cash flow hedges. There were no Euro forward contracts outstanding as of
March 31, 2017
or December 31, 2016.
The effect of the Company’s derivative instruments in its Condensed Consolidated Statements of Income and its Condensed Consolidated Statements of Comprehensive Income were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
March 31,
|
|
|
2017
|
|
2016
|
(In thousands)
|
|
|
|
|
Net gain (loss) recognized in OCI, net of tax
(1)
|
|
$
|
—
|
|
|
$
|
—
|
|
Gain (loss) reclassified from accumulated OCI into “Queen et al. royalty revenue,” net of tax
(2)
|
|
$
|
—
|
|
|
$
|
1,821
|
|
_______________________________
(1)
Net change in the fair value of cash flow hedges, net of tax.
(2)
Effective portion classified as royalty revenue.
7. Notes and Other Long-Term Receivables
Notes and other long-term receivables included the following significant agreements:
Wellstat Diagnostics Note Receivable and Credit Agreement
In March 2012, the Company executed a
$7.5 million
two
-year senior secured note receivable with the holders of the equity interests in Wellstat Diagnostics, LLC a/k/a Defined Diagnostics, LLC (“Wellstat Diagnostics”). In addition to bearing interest at
10%
per annum, the note receivable gave the Company certain rights to negotiate for certain future financing transactions. In August 2012, the Company and Wellstat Diagnostics amended the note receivable, providing a senior secured note receivable of
$10.0 million
, bearing interest at
12%
per annum, to replace the original
$7.5 million
note receivable. This
$10.0 million
note receivable was repaid on November 2, 2012, using the proceeds of the
$40.0 million
credit agreement entered into with the Company on the same date, as described below.
On November 2, 2012, the Company and Wellstat Diagnostics entered into a
$40.0 million
credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of
5%
per annum (payable in cash or in kind). In addition, the Company was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics’ products, if any, commencing upon the commercialization of its products.
In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. The Company sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, the Company exercised one of its available remedies and transferred approximately
$8.1 million
of available cash from a bank account of Wellstat Diagnostics to the Company and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby the Company agreed to refrain from exercising additional remedies for 120 days while Wellstat Diagnostics raised funds to capitalize the business and the parties attempted to negotiate a revised credit agreement. The Company agreed to provide up to
$7.9 million
to Wellstat Diagnostics to fund the business for the
120
-day forbearance period under the terms of the forbearance agreement. Following the conclusion of the forbearance period that ended on June 28, 2013, the Company agreed to forbear its exercise of remedies for additional periods of time to allow the owners and affiliates of Wellstat Diagnostics to complete a pending financing transaction. During such forbearance period, the Company provided approximately
$1.3 million
to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately
$8.7 million
was advanced pursuant to the forbearance agreement.
On August 15, 2013, the owners and affiliates of Wellstat Diagnostics completed a financing transaction to fulfill Wellstat Diagnostics’ obligations under the forbearance agreement. On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement.
Except as otherwise described herein, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of
5%
per annum (payable in cash or in kind). In addition, the Company was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately
$44.1 million
, which was comprised of approximately
$33.7 million
original loan
principal and interest,
$1.3 million
term loan principal and interest and
$9.1 million
forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics’ obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).
When the principal amount was reset, a
$2.5 million
reduction of the carrying value was recorded as a financing cost as a component of “Interest and other income, net”. The new carrying value is lower as a function of the variable nature of the internal rate of return to be realized by the Company based on when the note was to be repaid. The internal rate of return calculation, although increased, was reset when the credit agreement was amended and restated.
In June 2014, the Company received information from Wellstat Diagnostics showing that it was generally unable to pay its debts as they became due, constituting an event of default under the amended and restated credit agreement. Wellstat Diagnostics entered into a transaction involving another lender, pursuant to which Wellstat Diagnostics obtained additional short-term funding for its operations. At the same time, the Company entered into the first amendment to the amended and restated credit agreement with Wellstat Diagnostics. The material terms of the amendment included the following: (1) Wellstat Diagnostics acknowledged that an event of default had occurred; (2) the Company agreed to forbear from immediately enforcing its rights for up to 60 days, so long as the other lender provided agreed levels of interim funding to Wellstat Diagnostics; and (3) the Company obtained specified additional information rights with regard to Wellstat Diagnostics’ financial matters and investment banking activities.
On August 5, 2014, the Company received notice that the short-term funding being provided pursuant to the agreement with the other lender, entered into during June 2014, was being terminated. Wellstat Diagnostics remained in default because it was still unable to pay its debts as they became due. Accordingly, the Company delivered a notice of default (the “Wellstat Diagnostics Borrower Notice”). The Wellstat Diagnostics Borrower Notice accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately
$53.9 million
(which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations.
On August 7, 2014, the Company delivered a notice (the “Wellstat Diagnostics Guarantor Notice”) to each of Samuel J. Wohlstadter, Nadine H. Wohlstadter, Duck Farm, Inc., Hebron Valley Farms, Inc., HVF, Inc., Hyperion Catalysis EU Limited, Hyperion, NHW, LLC, Wellstat AVT Investment, LLC, Wellstat Biocatalysis, LLC, Wellstat Biologics Corporation, Wellstat Diagnostics, Wellstat Immunotherapeutics, LLC, Wellstat Management Company, LLC, Wellstat Opthalmics Corporation, Wellstat Therapeutics Corporation, Wellstat Therapeutics EU Limited, Wellstat Vaccines, LLC and SJW Properties, Inc., the guarantors of Wellstat Diagnostics’ obligations to the Company (collectively, the “Wellstat Diagnostics Guarantors”) under the credit agreement. The Wellstat Diagnostics Guarantor Notice included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.
On August 21, 2014, the Company entered into the second amendment to the amended and restated credit agreement with Wellstat Diagnostics, which amendment provided for the Company to make a discretionary advance to Wellstat Diagnostics.
On September 24, 2014, the Company filed an ex-parte petition for appointment of receiver with the Circuit Court of Montgomery County, Maryland (“the Wellstat Diagnostics Petition”), which was granted on the same day. The order granting the Wellstat Diagnostics Petition authorizes the receiver to take immediate possession of the physical assets of Wellstat Diagnostics, with the purpose of holding, protecting, insuring, managing and preserving the business of Wellstat Diagnostics and the value of the Company’s collateral. Wellstat Diagnostics has remained in operation during the period of the receivership with incremental additional funding from the Company.
On November 4, 2014, the Company entered into the third amendment to the amended and restated credit agreement with Wellstat Diagnostics. The amendment provides that additional funding, if any, to be made by the Company is conditioned upon the agreement by Wellstat Diagnostics to make certain operational changes within Wellstat Diagnostics, which the Company believes will allow the receiver to more efficiently optimize the value of the collateral.
During the second quarter of 2015, the receiver initiated a process for a public sale of the assets of Wellstat Diagnostics and retained the investment banking firm of Duff & Phelps to organize and manage the sale process. The receiver filed a “Motion for Approval of Sale Procedures” with the Circuit Court for Montgomery County, Maryland, which is the court having jurisdiction over the receivership and a hearing was held on July 22, 2015, at which time arguments were heard from interested parties regarding the sale procedures. No significant substantive disagreements between the parties regarding the sale procedures remained after the hearing and a decision approving the receiver’s sale procedures was made in the third quarter of 2015. The Company submitted a credit bid for the Wellstat Diagnostic assets at a value corresponding to some portion of the outstanding amount due under the amended and restated credit agreement which is subject to court approval. A hearing was scheduled in the Maryland Circuit Court for April 13, 2016 to hear the Receiver’s motion to approve the credit bid sale to the Company. However, on April 12, 2016, Wellstat Diagnostics changed its name to Defined Diagnostics, LLC and filed for bankruptcy under Chapter 11 in the United States Bankruptcy Court in the Southern District of New York. The filing of the bankruptcy case stays the proceedings in the Maryland Circuit Court pursuant to the automatic stay provisions of the Bankruptcy Code. On June 15, 2016, in response to a Motion to Dismiss filed by the Company alleging, among other things, that the New York Bankruptcy Court is not a proper venue for Defined Diagnostics to file for bankruptcy under Chapter 11, the New York Bankruptcy Court dismissed and transferred the action to the United States Bankruptcy Court in Delaware. On August 2, 2016 the Delaware Bankruptcy Court announced its decision to grant the Company’s motion to dismiss the chapter 11 petition with prejudice as a bad faith filing, which resulted in a lifting of the stay on the receivership sale in the Maryland Circuit Court. A hearing has been scheduled for December 22, 2016, in front of the Maryland Circuit Court related to the Company’s credit bid for Wellstat Diagnostics’ assets.
On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against certain of the Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, the Company filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantor defendants’ assets. At a hearing on September 24, 2015, regarding the Company’s request for a temporary restraining order, the court ordered that the Company’s request for attachment and for summary judgment would be heard at a hearing on November 5, 2015. Although the court denied the Company’s request for a temporary restraining order at the hearing on September 24, 2015, it ordered that assets of the Wellstat Diagnostics Guarantor defendants should be held in
status quo ante
and only used in the normal course of business pending the outcome of the matters under consideration at the hearing.
On July 29, 2016, the Supreme Court of New York issued its Memorandum of Decision granting the Company’s motion for summary judgment and denying the Wellstat Diagnostics Guarantors’ cross-motion for summary judgment. The Supreme Court of New York held that the Wellstat Diagnostics Guarantor defendants are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. It did not set a specific dollar amount due, but ordered that a judicial hearing officer or special referee be designated to determine the amount of the Obligations owing, and awarded the Company its attorneys’ fees and costs in an amount to be determined.
On July 29, 2016, the Wellstat Diagnostics Guarantor defendants filed a notice of appeal from the Memorandum of Decision to the Appellate Division of the Supreme Court of New York. On February 14, 2017, the Appellate Division of the Supreme Court of New York reversed on procedural grounds the portion of the Memorandum of Decision granting the Company summary judgment in lieu of complaint, but affirmed the portion of the Memorandum of Decision denying the Wellstat Diagnostics Guarantor defendants’ motion for summary judgment in which they sought a determination that the guarantees had been released. As a result, the litigation has been remanded to the Supreme Court of New York to proceed on the Company’s claims as a plenary action.
On September 1, 2016, the Company filed a motion for relief pursuant to New York law (i) restraining the Wellstat Diagnostics Guarantor defendants from making any sale, assignment, transfer or interference in any of their property, or from paying over or otherwise disposing of any debt and (ii) authorizing the Company to examine the assets of each of the Wellstat Diagnostics Guarantor defendants. On October 5, 2016, the Wellstat Diagnostics Guarantor defendants filed a motion for leave of the court to assert counterclaims against the Company, and certain officers and consultants of the Company, for (i) breach of fiduciary duty, (ii) intentional interference with prospective economic advantage, (iii) breach of the duty of good faith and fair dealing and negligent misrepresentation. A hearing date on the motion to assert counterclaims has yet to be set.
On October 14, 2016, the Company sent a notice of default and reference to foreclosure proceedings to certain of the Wellstat Diagnostics Guarantors which are not defendants in the New York action, but which are owners of real estate assets over which a deed of trust in favor of the Company securing the guarantee of the loan to Wellstat Diagnostics had been executed. On March 2, 2017, the Company sent a second notice to foreclose on the real estate assets, and noticed the sale for March 29, 2017. The sale was taken off the calendar by the trustee under the deed of trust and has not been re-scheduled yet. On March
6, 2017, the Company sent a letter to the Wellstat Diagnostics Guarantors seeking information in preparation for a UCC Article 9 sale of some or all of the intellectual property-related collateral of the Wellstat Diagnostics Guarantors. The Wellstat Diagnostics Guarantors did not respond to the Company’s letter, but on March 17, 2017, filed an order to show cause with the New York Supreme Court to enjoin the Company’s sale of the real estate or enforcing its security interests in the Wellstat Diagnostics Guarantors’ intellectual property during the pendency of any action involving the guarantees at issue. The court has not yet decided the Wellstat Diagnostics Guarantor motions.
On October 22, 2015, certain of the Wellstat Diagnostics Guarantors filed a separate complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect. This case is currently pending, but further action has been stayed pending a decision by the Supreme Court on whether to coordinate or consolidate the separate actions for pretrial purposes.
Through the period ended March 31, 2017, the Company has advanced to Wellstat Diagnostics
$19.1 million
to fund the ongoing operations of the business and other associated costs. This funding has been expensed as incurred.
Effective April 1, 2014, and as a result of the event of default, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At that time and as of March 31, 2017, it has been determined that an allowance on the carrying value of the note was not necessary, as the Company believes the value of the collateral securing Wellstat Diagnostics’ obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of
$50.2 million
. The Company continues to closely monitor the timing and expected recovery of amounts due, including litigation and other matters related to Wellstat Diagnostics Guarantors’ assets. There can be no assurance that an allowance on the carrying value of the notes receivable investment will not be necessary in a future period depending on future developments.
Hyperion Agreement
On January 27, 2012, the Company and Hyperion Catalysis International, Inc. (“Hyperion”) (which is also a Wellstat Diagnostics Guarantor) entered into an agreement whereby Hyperion sold to the Company the royalty streams due from SDK related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. The agreement assigned the patent license agreement royalty stream accruing from January 1, 2012 through December 31, 2013, to the Company in exchange for the lump sum payment to Hyperion of
$2.3 million
. In exchange for the lump sum payment, the Company was to receive
two
equal payments of
$1.2 million
on each of March 5, 2013 and 2014. The first payment of
$1.2 million
was paid on March 5, 2013, but Hyperion has not made the second payment that was due on March 5, 2014. The Company completed an impairment analysis as of March 31, 2017. Effective with this date and as a result of the event of default, the Company ceased to accrue interest revenue. As of March 31, 2017, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance that this will be true in the event of the Company’s foreclosure on the collateral, nor can there be any assurance of realizing value from such collateral.
Avinger Credit and Royalty Agreement
Under the terms of the Avinger Credit and Royalty Agreement, the Company receives a low, single-digit royalty on Avinger’s net revenues until April 2018. Commencing in October 2015, after Avinger repaid
$21.4 million
pursuant to its note receivable prior to its maturity date, the royalty on Avinger’s net revenues reduce by
50%
, subject to certain minimum payments from the prepayment date until April 2018. The Company has accounted for the royalty rights in accordance with the fair value option. For a further discussion of the Avinger Credit and Royalty Agreement, see Note 3.
LENSAR Credit Agreement
On October 1, 2013, the Company entered into a credit agreement with LENSAR, Inc. (“LENSAR”), pursuant to which the Company made available to LENSAR up to
$60.0 million
to be used by LENSAR in connection with the commercialization of its currently marketed LENSAR™ Laser System. Of the
$60.0 million
available to LENSAR, an initial
$40.0 million
, net of fees, was funded by the Company at the close of the transaction. The remaining
$20.0 million
, in the form of a second tranche is no longer available to LENSAR under the terms of the credit agreement. Outstanding borrowings under the loans bore interest at the rate of
15.5%
per annum, payable quarterly in arrears.
On May 12, 2015, the Company entered into a forbearance agreement with LENSAR, pursuant to which the Company agreed to refrain from exercising certain remedies available to it resulting from the failure of LENSAR to comply with a liquidity covenant and make interest payments due under the credit agreement. Under the forbearance agreement, the Company agreed
to provide LENSAR with up to an aggregate of
$8.5 million
in weekly increments through the period ended September 30, 2015 plus employee retention amounts of approximately
$0.5 million
in the form of additional loans, subject to LENSAR meeting certain milestones related to LENSAR obtaining additional capital to fund the business or sell the business and repay outstanding amounts under the credit agreement. In exchange for the forbearance, LENSAR agreed to additional reporting covenants, the engagement of a chief restructuring officer and an increase on the interest rate to
18.5%
, applicable to all outstanding amounts under the credit agreement.
On September 30, 2015, the Company agreed to extend the forbearance agreement until October 9, 2015 and provide for up to an additional
$0.8 million
in funding while LENSAR negotiated a potential sale of its assets. On October 9, 2015, the forbearance agreement expired, but the Company agreed to fund LENSAR’s operations while LENSAR continued to negotiate a potential sale of its assets.
On November 15, 2015, LENSAR, LLC (“LENSAR/Alphaeon”), a wholly owned subsidiary of Alphaeon Corporation (“Alphaeon”), and LENSAR entered into the Asset Purchase Agreement whereby LENSAR/Alphaeon agreed to acquire certain assets of LENSAR and assumed certain liabilities of LENSAR. The acquisition was consummated on December 15, 2015.
In connection with the closing of the acquisition, LENSAR/Alphaeon entered into an amended and restated credit agreement with the Company, assuming
$42.0 million
in loans as part of the borrowings under the Company’s prior credit agreement with LENSAR. In addition, Alphaeon issued
1.7 million
shares of its Class A common stock to the Company.
The Company has estimated a fair value of
$3.84
per share for the
1.7 million
shares of Alphaeon Class A common stock received in connection with the transactions and recognized this investment as a cost-method investment of
$6.6 million
included in other long-term asset. The Alphaeon Class A common stock is subject to other-than-temporary impairment assessments in future periods. There is no other-than-temporary impairment charge incurred as of March 31, 2017.
In December 2016, LENSAR, re-acquired the assets from LENSAR/Alphaeon and the Company entered into an amended and restated credit agreement with LENSAR whereby LENSAR assumed all obligations outstanding under the credit agreement with LENSAR/Alphaeon. Also in December, LENSAR filed for a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code (“Chapter 11 case”) with the support of the Company. In January 2017, the Company agreed to provide debtor-in-possession financing of up to
$2.8 million
in new advances to LENSAR so that it can continue to operate its business during the remainder of the Chapter 11 case. LENSAR has filed a Chapter 11 plan of reorganization with the Company’s support under which LENSAR will issue 100% of its equity securities to the Company in exchange for the cancellation of the Company’s claims as a secured creditor in the Chapter 11 case, other than with respect to the debtor-in-possession financing, and will become an operating subsidiary of the Company.
On April 26, 2017 the bankruptcy court approved the plan of reorganization, and the Company expects that LENSAR will emerge from the Chapter 11 case on or about May 11, 2017.
The Company completed an impairment analysis as of March 31, 2017. Effective with this date and as a result of the event of default, the Company determined the loan to be impaired and the Company ceased to accrue interest revenue. As of March 31, 2017, the estimated fair value of the collateral would be sufficient to recover the carrying value. There can be no assurance that this will be true, nor can there be any assurance of realizing value from such collateral.
Direct Flow Medical Credit Agreement
On November 5, 2013, the Company entered into a credit agreement with Direct Flow Medical, Inc. (“Direct Flow Medical”) under which the Company agreed to provide up to
$50.0 million
to Direct Flow Medical. Of the
$50.0 million
available to Direct Flow Medical, an initial
$35.0 million
(tranche one), net of fees, was funded by the Company at the close of the transaction. Pursuant to the original terms of the credit agreement the Company agreed to provide Direct Flow Medical with an additional
$15.0 million
tranche, net of fees, upon the attainment of a specified revenue milestone to be accomplished no later than December 31, 2014 (the tranche two milestone). Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bore interest at the rate of
15.5%
per annum, payable quarterly in arrears.
On November 10, 2014, the Company and Direct Flow Medical agreed to an amendment to the credit agreement to permit Direct Flow Medical to borrow the
$15.0 million
second tranche upon receipt by Direct Flow Medical of a specified minimum amount of proceeds from an equity offering prior to December 31, 2014. In exchange, the parties amended the credit agreement to provide for additional fees associated with certain liquidity events, such as a change of control or the consummation of an initial public offering, and granted the Company certain board of director observation rights. On November 19, 2014, upon Direct Flow Medical satisfying the amended tranche two milestone, the Company funded the
$15.0 million
second tranche to
Direct Flow Medical, net of fees. Upon occurrence of the borrowing of this second tranche, the interest rate applicable to all loans under the credit agreement was decreased to
13.5%
per annum, payable quarterly in arrears.
Under the terms of the credit agreement, Direct Flow Medical’s obligation to repay loan principal commenced on the twelfth interest payment date, September 30, 2016. The principal amount outstanding at commencement of repayment is required to be repaid in equal installments until final maturity of the loans. The loans mature on November 5, 2018. Direct Flow Medical may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the credit agreement are secured by a pledge of substantially all the assets of Direct Flow Medical and any of its subsidiaries.
On December 21, 2015, Direct Flow Medical and the Company entered into a waiver to the credit agreement in anticipation of Direct Flow Medical being unable to comply with the liquidity covenant and make interest payments due under the credit agreement.
On January 14, 2016, both parties agreed to provide Direct Flow Medical with an extension to waive the liquidity covenant and delay the timing of the interest payments through the period ending September 30, 2016 while Direct Flow Medical sought additional financing to operate its business.
On January 28, 2016, the Company funded an additional
$5.0 million
to Direct Flow Medical in the form of a short-term secured promissory note.
On February 26, 2016, the Company and Direct Flow Medical entered into the fourth amendment to the credit agreement that, among other things, (i) converted the
$5.0 million
short-term secured promissory note into a loan under the credit agreement with substantially the same interest and payment terms as the existing loans, (ii) added a conversion feature whereby the
$5.0 million
loan would convert into equity of Direct Flow Medical upon the occurrence of certain events and (iii) provided for a second
$5.0 million
convertible loan tranche commitment, to be funded at the option of the Company. The commitment for the second tranche was not funded and has since expired. In addition, (i) the Company agreed to waive the liquidity covenant and delay the timing of the unpaid interest payments until September 30, 2016 and (ii) Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock on the first day of each month for the duration of the waiver period at an exercise price of
$0.01
per share.
On July 15, 2016, the Company and Direct Flow Medical entered into the fifth amendment and limited waiver to the credit agreement. The Company funded an additional
$1.5 million
to Direct Flow Medical in the form of a note with substantially the same interest and payment terms as the existing loans and a conversion feature whereby the
$1.5 million
loan would convert into equity of Direct Flow Medical upon the occurrence of certain events. In addition, Direct Flow Medical agreed to issue to the Company warrants to purchase shares of convertible preferred stock at an exercise price of
$0.01
per share.
On September 12, 2016, the Company and Direct Flow Medical entered into the sixth amendment and limited waiver to the credit agreement under which the Company funded an additional
$1.5 million
to Direct Flow Medical in the form of a note with substantially the same interest and payment terms as the existing loans. In addition, Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock at an exercise price of
$0.01
per share.
On September 30, 2016, the Company and Direct Flow Medical entered into the tenth limited waiver to the credit agreement where the parties agreed, among other things, to (i) delay payment on all overdue interest payments until October 31, 2016, (ii) waive the initial principal repayment until October 31, 2016 and (iii) continue to waive the liquidity requirements until October 31, 2016. Further, Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock at an exercise price of
$0.01
per share.
On October 31, 2016, the Company agreed to extend the waivers described above until November 30, 2016 and on November 14, 2016, the Company advanced an additional
$1.0 million
loan while Direct Flow Medical continued to seek additional financing.
On November 16, 2016, Direct Flow Medical advised the Company that its potential financing source had modified its proposal from an equity investment to a loan with a substantially smaller amount and under less favorable terms. Direct Flow Medical shut down its operations in December 2016 and in January 2017 made an assignment for the benefit of creditors. The Company then initiated foreclosure proceedings, resulting in the Company obtaining ownership of most of the Direct Flow Medical assets through its wholly-owned subsidiary, DFM, LLC. The assets are held for sale and carried at the lower of
carrying amount or fair value, less estimated selling costs, which is primarily based on supporting data from market participant sources, and valid offers from third parties.
At December 31, 2016, the Company completed an impairment analysis and concluded that the situation qualified as a troubled debt restructuring and recognized an impairment loss of
$51.1 million
.
In January 2017, the Company started to actively market the asset held for sale. On January 23, 2017, the Company and DFM, LLC entered into an Intellectual Property Assignment Agreement with Hong Kong Haisco Pharmaceutical Co., Limited (“Haisco”), a Chinese pharmaceutical company, whereby Haisco acquired former Direct Flow Medical clinical, regulatory and commercial information and intellectual property rights exclusively in China for
$7.0 million
. The Company also sold Haisco certain manufacturing equipment for
$450,000
and collected
$438,000
on outstanding Direct Flow Medical accounts receivable during the first quarter of 2017. The Company is exploring alternatives to further monetize the remaining assets of Direct Flow Medical and has ascribed a carrying value of
$2.1 million
to the remaining assets held for sale at March 31, 2017.
Paradigm Spine Credit Agreement
On February 14, 2014, the Company entered into the Credit Agreement (the “Paradigm Spine Credit Agreement”) with Paradigm Spine, LLC (“Paradigm Spine”), under which it made available to Paradigm Spine up to
$75.0 million
to be used by Paradigm Spine to refinance its existing credit facility and expand its domestic commercial operations. Of the
$75.0 million
available to Paradigm Spine, an initial
$50.0 million
, net of fees, was funded by the Company at the close of the transaction. The second and third tranches of up to an additional
$25.0 million
in the aggregate, net of fees, are no longer available under the terms of the Paradigm Spine Credit Agreement.
On October 27, 2015, the Company and Paradigm Spine entered into an amendment to the Paradigm Spine Credit Agreement to provide additional term loan commitments of up to
$7.0 million
payable in two tranches, of which the first tranche of
$4.0 million
was drawn on the closing date of the amendment, net of fees. Paradigm Spine chose not to draw down the second tranche of
$3.0 million
and such tranche is no longer available. Borrowings under the credit agreement bore interest at the rate of
13.0%
per annum, payable quarterly in arrears.
On August 26, 2016, the Company received
$57.5 million
in connection with the prepayment of the loans under the Paradigm Spine Credit Agreement, which included a repayment of the full principal amount outstanding of
$54.7 million
, plus accrued interest and a prepayment fee.
kaléo Note Purchase Agreement
On April 1, 2014, the Company entered into a note purchase agreement with Accel 300, LLC (“Accel 300”), a wholly-owned subsidiary of kaléo, Inc. (“kaléo”), pursuant to which the Company acquired
$150.0 million
of secured notes due 2029. The secured notes were issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and are secured by 20% of net sales of its first approved product, Auvi-Q
®
(epinephrine auto-injection, USP) (known as Allerject
®
in Canada) and 10% of net sales of kaléo’s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection ) (the “kaléo Revenue Interests”), and a pledge of kaléo’s equity ownership in Accel 300.
The secured notes bear interest at
13%
per annum, paid quarterly in arrears on principal outstanding. The principal balance of the secured notes is repaid to the extent that the kaléo Revenue Interests exceed the quarterly interest payment, as limited by a quarterly payment cap. The final maturity of the secured notes is June 2029. kaléo may redeem the secured notes at any time, subject to a redemption premium.
On October 28, 2015, Sanofi US initiated a voluntary nationwide recall of all Auvi-Q
units effectively immediately because in rare cases the syringe would not deliver the proper amount of epinephrine, the drug used to treat severe allergic reactions. Sanofi was the exclusive licensee of kaléo for the manufacturing and commercialization of Auvi-Q.
In March 2016, Sanofi and kaléo terminated their license and development agreement and all U.S. and Canadian commercial and manufacturing rights to Auvi-Q
®
and Allerject
®
, and manufacturing equipment, were returned to kaléo. As part of the financing transaction, kaléo was required to establish an interest reserve account of
$20.0 million
from the
$150.0 million
provided by the Company. The purpose of this interest reserve account is to cover any possible shortfalls in interest payments owed to the Company. While the interest reserve account was depleted in the second quarter of 2016, kaléo continues to make interest payments due to the Company under the note purchase agreement and the Company expects that kaléo will fund future
interest payments with existing cash to the extent that the kaléo Revenue Interests are insufficient during the reintroduction of Auvi-Q to the market. kaléo reintroduced Auvi-Q to the U.S. market on February 14, 2017.
As of
March 31, 2017
, the Company determined that its royalty purchase interest in Accel 300 represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Accel 300 that most significantly impact Accel 300’s economic performance and is not the primary beneficiary of Accel 300; therefore, Accel 300 is not subject to consolidation by the Company.
CareView Credit Agreement
On June 26, 2015, the Company entered into a credit agreement with CareView Communications Inc. (“Careview”), under which the Company made available to CareView up to
$40.0 million
in two tranches of
$20.0 million
each. Under the terms of the credit agreement, the first tranche of
$20.0 million
, net of fees, was funded by the Company upon CareView’s attainment of a specified milestone relating to the placement of CareView Systems
®
, on October 7, 2015. The second
$20.0 million
tranche would be funded upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and consolidated earnings before interest, taxes, depreciation and amortization, to be accomplished no later than June 30, 2017. Outstanding borrowings under the credit agreement will bear interest at the rate of
13.5%
per annum and are payable quarterly in arrears.
As part of the transaction, the Company received a warrant to purchase approximately
4.4 million
shares of common stock of CareView at an exercise price of
$0.45
per share. The Company has accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.
On October 7, 2015, the Company and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones.
In connection with the amendment of the credit agreement, the Company and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant’s exercise price from
$0.45
to
$0.40
per share. At
March 31, 2017
, the Company determined an estimated fair value of the warrant of
$0.2 million
.
For carrying value and fair value information related to the Company’s Notes and Other Long-term Receivables, see Note 3.
8. Inventory
Inventories consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
December 31,
|
|
|
2017
|
|
2016
|
Work in process
|
|
$
|
2,406
|
|
|
$
|
1,625
|
|
Finished goods
|
|
1,127
|
|
|
1,259
|
|
Total inventory
|
|
$
|
3,533
|
|
|
$
|
2,884
|
|
In addition, as of March 31, 2017 and December 31, 2016, the Company deferred approximately
$0.5 million
and
$0.1 million
, respectively, of costs associated with inventory transfer made under the Company’s third party logistic provider service arrangement. These costs have been recorded as other assets on the Company’s Condensed Consolidated Balance Sheet as of March 31, 2017 and December 31, 2016. The Company will recognize the cost of product sold as inventory is transferred from its third party logistic provider to the Company’s customers.
During the first quarter of 2017 and fourth quarter of 2016, the Company recognized an inventory write-down of
$0.1 million
and
$0.3 million
related to Noden Products that the Company would not be able to sell prior to their expiration.
9. Intangible Assets and Goodwill
Intangible Assets, Net
The components of intangible assets as of March 31, 2017 and December 31, 2016 were as follows (in thousands, except for useful life):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2017
|
|
December 31, 2016
|
(in thousands)
|
|
Cost
|
|
Accumulated Amortization
|
|
Net
|
|
Cost
|
|
Accumulated Amortization
|
|
Net
|
Finite-lived intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquired products rights
(1)
|
|
$
|
216,690
|
|
|
$
|
(16,252
|
)
|
|
$
|
200,438
|
|
|
$
|
216,690
|
|
|
$
|
(10,834
|
)
|
|
$
|
205,856
|
|
Customer relationships
(1)
|
|
23,880
|
|
|
(1,791
|
)
|
|
22,089
|
|
|
23,880
|
|
|
(1,194
|
)
|
|
22,686
|
|
|
|
$
|
240,570
|
|
|
$
|
(18,043
|
)
|
|
$
|
222,527
|
|
|
$
|
240,570
|
|
|
$
|
(12,028
|
)
|
|
$
|
228,542
|
|
________________
(1) We acquired certain intangible assets as part of the Noden Transaction, as described further in Note 16. They are amortized on a straight line basis over a weighted average of
10.0 years
.
Amortization expense for the three months ended March 31, 2017 was
$6.0 million
.
Based on the intangible assets recorded at March 31, 2017, and assuming no subsequent additions to or impairment of the underlying assets, the remaining estimated amortization expense is expected to be as follows (in thousands):
|
|
|
|
|
|
Fiscal Year
|
|
Amount
|
2017 (Remaining nine months)
|
|
$
|
18,043
|
|
2018
|
|
24,057
|
|
2019
|
|
24,057
|
|
2020
|
|
24,057
|
|
2021
|
|
24,057
|
|
2022
|
|
24,057
|
|
Thereafter
|
|
84,199
|
|
Total purchased intangible assets
|
|
$
|
222,527
|
|
Goodwill
Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. The Company applies ASC 350,
Goodwill and Other Intangible Assets
, which requires testing goodwill for impairment on an annual basis. The Company assesses goodwill for impairment as part of its annual reporting process in the fourth quarter. The Company evaluates goodwill on a reporting unit basis as the Company is organized as a multiple reporting unit.
The Company’s projected cash flows for the Noden Products decreased significantly during the fourth quarter of 2016 as the Company obtained new information relating to the Noden Products in December 2016. The Company concluded that, given this significant and sustained decrease in projected cash flows, a triggering event requiring an assessment of goodwill impairment had occurred during the fourth quarter of 2016. The Company performed the goodwill impairment assessment using an income approach, which is forward-looking, and relies primarily on internal forecasts. Within the income approach, the Company used the discounted cash flow method. The Company starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a reporting unit-specific discount rate to arrive at a net present value. Some of the more significant estimates and assumptions inherent in this approach include (i) the amount and timing of the projected net cash flows, (ii) the selection of a long-term growth rate, (iii) the discount rate, which seeks to reflect the various risks inherent in the projected cash flows and (iv) the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
The initial assessment indicated that it was likely the Company’s goodwill was impaired, and the Company proceeded to perform a full goodwill impairment assessment. As a result of that assessment, the Company concluded that a goodwill
impairment loss of
$3.7 million
was necessary. Following the recording of the goodwill impairment loss, the Company’s goodwill as of March 31, 2017 and December 31, 2016 was zero.
10. Accrued Liabilities
Accrued liabilities consist of the following:
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
March 31,
2017
|
|
December 31,
2016
|
Compensation
|
|
$
|
4,199
|
|
|
$
|
3,131
|
|
Interest
|
|
2,321
|
|
|
2,554
|
|
Dividend payable
|
|
122
|
|
|
21
|
|
Legal
|
|
1,083
|
|
|
1,594
|
|
Accrued rebates, chargebacks and other revenue reserves
|
|
17,066
|
|
|
12,338
|
|
Refund to manufacturer
|
|
8,909
|
|
|
8,909
|
|
Other
|
|
3,100
|
|
|
2,028
|
|
Total
|
|
$
|
36,800
|
|
|
$
|
30,575
|
|
The following table provides a summary of activity with respect to the Company’s sales allowances and accruals for the three months ended March 31, 2017:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
Discount and Distribution Fees
|
|
Government Rebates and Chargebacks
|
|
Assistance and Other Discounts
|
|
Product Return
|
|
Total
|
Balance at December 31, 2016:
|
|
$
|
2,475
|
|
|
$
|
5,514
|
|
|
$
|
2,580
|
|
|
$
|
1,769
|
|
|
$
|
12,338
|
|
Allowances for current period sales
|
|
2,243
|
|
|
4,939
|
|
|
2,264
|
|
|
1,235
|
|
|
10,681
|
|
Allowances for prior period sales
|
|
—
|
|
|
253
|
|
|
—
|
|
|
—
|
|
|
253
|
|
Credits/payments for current period sales
|
|
(453
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(453
|
)
|
Credits/payments for prior period sales
|
|
(1,451
|
)
|
|
(3,746
|
)
|
|
(556
|
)
|
|
—
|
|
|
(5,753
|
)
|
Balance at March 31, 2017
|
|
$
|
2,814
|
|
|
$
|
6,960
|
|
|
$
|
4,288
|
|
|
$
|
3,004
|
|
|
$
|
17,066
|
|
11. Commitments and Contingencies
PDL BioPharma, Inc. v Merck Sharp & Dohme, Corp.
On October 28, 2015, the Company filed a Complaint against Merck Sharp & Dohme, Corp (“Merck”) for patent infringement in the United States District Court for the District of Nevada. In the Complaint, the Company alleged that manufacture and sales of certain of Merck’s Keytruda product infringed one or more claims of the Company’s U.S. Patent No. 5,693,761 (the “761 Patent”). The Company requested judgment that Merck infringed the 761 Patent, an award of damages due to the infringement, a finding that such infringement was willful and deliberate and trebling of damages therefore, and a declaration that the case is exceptional and warrants an award of attorney’s fees and costs. Although the 761 Patent expired on December 2, 2014, the Company believed that Merck infringed the patent through, e.g., manufacture and/or sale of Keytruda prior to the expiration of the 761 Patent. On December 21, 2015, Merck filed a Motion to Dismiss for Lack of Personal Jurisdiction. In response to Merck’s motion, on January 22, 2016, rather than dispute Merck’s contentions regarding jurisdiction, the Company elected to dismiss the action in Nevada and refile the Complaint in its entirety in the District of New Jersey. On May 25, 2016, Merck filed a Motion to Bifurcate Discovery and Trial into Liability and Damages Phases, which motion was granted by the court.
On April 21, 2017, the Company entered into a settlement agreement with Merck to resolve the patent infringement lawsuit between the parties pending in the U.S. District Court for the District of New Jersey related to Merck’s Keytruda humanized antibody product. Under the terms of the agreement, Merck will pay the Company a one time, lump-sum payment of
$19.5 million
, and the Company will grant Merck a fully paid-up, royalty free, non-exclusive license to certain of the Company’s rights to issued patents in the United States and elsewhere, covering the humanization of antibodies (the “Queen et al. patent”) for use in connection with Keytruda as well as a covenant not to sue Merck for any royalties regarding Keytruda. In addition, the parties agreed to dismiss all claims in the relevant legal proceedings.
Wellstat Litigation
On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On July 29, 2016, the court issued its Memorandum of Decision granting the Company’s motion for summary judgment and denying the Wellstat Diagnostics Guarantors’ cross-motion for summary judgment seeking a determination that they were no longer liable under the guarantees. The Supreme Court of New York held that the Wellstat Diagnostics Guarantors are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. It did not set a specific dollar amount due, but ordered that a judicial hearing officer or special referee be designated to determine the amount of the Obligations owing, and awarded the Company its attorneys’ fees and costs in an amount to be determined. On July 29, 2016, the Wellstat Diagnostics Guarantors filed a notice of appeal from the Memorandum of Decision to the Appellate Division of the Supreme Court of New York. On February 14, 2017, the Appellate Division reversed the summary judgment decision of the Supreme Court in the Company’s favor, but affirmed the denial of the Wellstat Guarantors’ cross-motion for summary judgment. The Appellate Division determined that the action was inappropriate for summary judgment pursuant to New York Civil Practice Law & Rules section 3213 on procedural grounds, but specifically made no determination regarding whether the Company was entitled to a judgment on the merits. Pursuant to this decision, the action will be remanded to the Supreme Court for further proceedings on the merits. The proceeding will be conducted as a plenary proceeding, with both parties having the opportunity to take discovery and file dispositive motions in accordance with New York civil procedure.
Other Legal Proceedings
From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of the Company’s operations of that period and on its cash flows and liquidity.
Lease Guarantee
In connection with the spin-off (the “Spin-Off”) by the Company of Facet Biotech Corporation (“Facet”), the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. As of
March 31, 2017
, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately
$53.6 million
. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (“AbbVie”). If AbbVie were to default under its lease obligations, the Company could be held liable by the landlord as a co-tenant and, thus, the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities.
The Company prepared a discounted, probability weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the Spin-Off. The Company was required to make assumptions regarding the probability of Facet’s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that we received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to additional paid-in capital upon the Spin-Off and any future adjustments to the carrying value of the obligation will also be recorded in additional paid-in capital.
The Company has recorded a liability of
$10.7 million
on its Condensed Consolidated Balance Sheets as of
March 31, 2017
and December 31, 2016, related to this guarantee. In future periods, the Company may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.
Irrevocable Letters of Credit
On June 30, 2016, the Company purchased a
$75.0 million
certificate of deposit, which is designated as cash collateral for the
$75.0 million
letter of credit issued on July 1, 2016 with respect to the first anniversary payment under the Noden Purchase Agreement (as defined in Note 16 below). In addition, we provided an irrevocable and unconditional guarantee to Novartis
Pharma AG (“Novartis”), to pay up to
$14.0 million
of the remaining amount of the first anniversary payment not covered by the letter of credit. The Company concluded that both guarantees are contingent obligations and shall be accounted for in accordance with ASC 450,
Contingencies
. Further, it was concluded that both guarantees do not meet the conditions to be accrued at
March 31, 2017
.
Purchase Obligation
In connection with the Noden Transaction, Noden entered into an unconditional purchase obligation with Novartis to acquire all local finished goods inventory in certain countries upon transfer of the applicable marketing authorization rights in such country. The purchase is payable within 60 days after the transfer of the marketing authorization rights. The agreement does not specify minimum quantities but details pricing terms.
In addition, Noden and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden a finished form of the Noden Products and bulk drug form of the Noden Products for specified periods of time prior to the transfer of manufacturing responsibilities for the Noden Products to another manufacturer. The supply agreement commits the Company to a minimum purchase obligation of approximately
$9.6 million
and
$120.7 million
over the next twelve and twenty-four months, respectively. The Company expects to meet this requirement. For more information about the Noden Transaction, see Note 16 below.
12. Convertible Notes and Term Loans
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal Balance Outstanding
|
|
Carrying Value
|
|
|
|
|
|
March 31,
|
|
March 31,
|
|
December 31,
|
|
Description
|
|
Maturity Date
|
|
2017
|
|
2017
|
|
2016
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
Convertible Notes
|
|
|
|
|
|
|
|
|
|
February 2018 Notes
|
|
February 1, 2018
|
|
$
|
126,447
|
|
|
$
|
122,692
|
|
|
$
|
121,595
|
|
|
December 2021 Notes
|
|
December 1, 2021
|
|
$
|
150,000
|
|
|
112,426
|
|
|
110,848
|
|
|
Total
|
|
|
|
|
|
|
$
|
235,118
|
|
|
$
|
232,443
|
|
|
February 2018 Notes
On February 12, 2014, the Company issued
$300.0 million
in aggregate principal amount, at par, of the February 2018 Notes in an underwritten public offering, for net proceeds of
$290.2 million
. The February 2018 Notes are due February 1, 2018, and the Company pays interest at
4.0%
on the February 2018 Notes semiannually in arrears on February 1 and August 1 of each year, beginning August 1, 2014. A portion of the proceeds from the February 2018 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem
$131.7 million
of the Company’s 2.975% Convertible Senior Notes due February 17, 2016. Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require the Company to repurchase their February 2018 Notes at a purchase price equal to
100%
of the principal, plus accrued interest.
On November 20, 2015, the Company’s agent initiated the repurchase of
$53.6 million
in aggregate principal amount of its February 2018 Notes for
$43.7 million
in cash in four open market transactions. The closing of these transactions occurred on November 30, 2015. It was determined that the repurchase of the principal amount shall be accounted for as a partial extinguishment of the February 2018 Notes. As a result, a gain on extinguishment of
$6.5 million
was recorded at closing of the transaction. The
$6.5 million
gain on extinguishment included the de-recognition of the original issuance discount of
$3.1 million
, outstanding deferred issuance costs of
$0.9 million
and agent fees of
$0.1 million
. Immediately following the repurchase,
$246.4 million
principal amount of the February 2018 Notes was outstanding with
$14.1 million
of remaining original issuance discount and
$4.1 million
of debt issuance costs to be amortized over the remaining life of the February 2018 Notes.
In connection with this repurchase of the February 2018 Notes, the Company unwound a portion of the purchased call options related to the notes. As a result of this unwinding, the Company received
$270,000
in cash. The payments received have been recorded as an increase to additional paid-in-capital. In addition, the Company unwound a portion of the warrants for
$170,000
in cash, payable by the Company. The payments have been recorded as a decrease to additional paid-in-capital. At the time of
the transaction, the Company concluded that the remaining purchased call options and warrants continue to meet all criteria for equity classification.
On November 22, 2016, the Company repurchased
$120.0 million
in aggregate principal amount of its February 2018 Notes for approximately
$121.5 million
in cash (including
$1.5 million
of accrued interest) in open market transactions. It was determined that the repurchase of the principal amount shall be accounted for as an extinguishment. The extinguishment included the de-recognition of the original issuance discount of
$4.3 million
and outstanding deferred issuance costs of
$1.3 million
. Immediately following the repurchase,
$126.4 million
principal amount of the February 2018 Notes was outstanding with
$4.6 million
of remaining original issuance discount and
$1.4 million
of debt issuance costs to be amortized over the remaining life of the February 2018 Notes.
In connection with the repurchase of the February 2018 Notes, the Company unwound a portion of the purchased call options. The unwind transaction of the purchased call option did not result in any cash payments between the parties. In addition, the Company and the counterparties agreed to unwind a portion of the warrants, which also did not result in any cash payments between the parties. At the time of the transaction, the Company concluded that the remaining purchased call options and warrants continue to meet all criteria for equity classification.
The February 2018 Notes are convertible under any of the following circumstances:
|
|
•
|
During any fiscal quarter ending after the quarter ended June 30, 2014, if the last reported sale price of the Company’s common stock for at least
20
trading days in a period of
30
consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds
130%
of the conversion price for the notes on the last day of such preceding fiscal quarter;
|
|
|
•
|
During the five business-day period immediately after any five consecutive trading-day period in which the trading price per
$1,000
principal amount of notes for each trading day of that measurement period was less than
98%
of the product of the last reported sale price of the Company’s common stock and the conversion rate for the notes for each such day;
|
|
|
•
|
Upon the occurrence of specified corporate events as described further in the indenture; or
|
|
|
•
|
At any time on or after August 1, 2017.
|
The initial conversion rate for the February 2018 Notes is
109.1048
shares of the Company’s common stock per
$1,000
principal amount of February 2018 Notes, which is equivalent to an initial conversion price of approximately
$9.17
per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the indenture. Upon conversion, the Company will be required to pay cash and, if applicable, deliver shares of the Company’s common stock as described in the indenture.
As of
March 31, 2017
, the Company’s February 2018 Notes are not convertible. At
March 31, 2017
, the if-converted value of the February 2018 Notes did not exceed the principal amount.
In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the February 2018 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of
7.0%
, which represents the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of
$29.7 million
, allocated
$19.3 million
to additional paid-in capital and allocated
$10.4 million
to deferred tax liability. The discount is being amortized to interest expense over the term of the February 2018 Notes and increases interest expense during the term of the February 2018 Notes from the
4.0%
cash coupon interest rate to an effective interest rate of
6.9%
. As of
March 31, 2017
, the remaining discount amortization period is
0.9 years
.
The carrying value and unamortized discount of the February 2018 Notes were as follows:
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
March 31, 2017
|
|
December 31, 2016
|
Principal amount of the February 2018 Notes
|
|
$
|
126,447
|
|
|
$
|
126,447
|
|
Unamortized discount of liability component
|
|
(3,755
|
)
|
|
(4,852
|
)
|
Net carrying value of the February 2018 Notes
|
|
$
|
122,692
|
|
|
$
|
121,595
|
|
Interest expense for the February 2018 Notes on the Company’s Condensed Consolidated Statements of Income was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
March 31,
|
(In thousands)
|
|
2017
|
|
2016
|
Contractual coupon interest
|
|
$
|
1,265
|
|
|
$
|
2,464
|
|
Amortization of debt issuance costs
|
|
249
|
|
|
438
|
|
Amortization of debt discount
|
|
848
|
|
|
1,550
|
|
Total
|
|
$
|
2,362
|
|
|
$
|
4,452
|
|
Purchased Call Options and Warrants
In connection with the issuance of the February 2018 Notes, the Company entered into purchased call option transactions with two hedge counterparties. The Company paid an aggregate amount of
$31.0 million
for the purchased call options with terms substantially similar to the embedded conversion options in the February 2018 Notes. The purchased call options cover, subject to anti-dilution and certain other customary adjustments substantially similar to those in the February 2018 Notes, approximately
13.8 million
shares of the Company’s common stock. The Company may exercise the purchased call options upon conversion of the February 2018 Notes and require the hedge counterparty to deliver shares to the Company in an amount equal to the shares required to be delivered by the Company to the note holder for the excess conversion value. The purchased call options expire on February 1, 2018, or the last day any of the February 2018 Notes remain outstanding.
In addition, the Company sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive shares of common stock that will initially underlie the February 2018 Notes at a strike price of
$10.3610
per share, which represents a premium of approximately 30% over the last reported sale price of the Company’s common stock of
$7.97
on February 6, 2014. The warrant transactions could have a dilutive effect to the extent that the market price of the Company’s common stock exceeds the applicable strike price of the warrants on the date of conversion. The Company received an aggregate amount of
$11.4 million
for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates that occur over a period of time. If the VWAP of the Company’s common stock, as defined in the warrants, exceeds the strike price of the warrants, the Company will deliver to the warrant counterparties shares equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.
The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of the February 2018 Notes. The strike price is subject to further adjustment in the event that future quarterly dividends exceed
$0.15
per share.
The purchased call options and warrants are considered indexed to the Company stock, require net-share settlement, and met all criteria for equity classification at inception and at
March 31, 2017
. The purchased call options cost of
$31.0 million
, less deferred taxes of
$10.8 million
, and the
$11.4 million
received for the warrants, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the purchased call options and warrants continue to meet the criteria for equity classification.
December 2021 Notes
On November 22, 2016, the Company issued
$150.0 million
in aggregate principal amount, at par, of the December 2021 Notes in an underwritten public offering, for net proceeds of
$145.7 million
. The December 2021 Notes are due December 1, 2021, and the Company pays interest at
2.75%
on the December 2021 Notes semiannually in arrears on June 1 and December 1 of each year, beginning June 1, 2017. A portion of the proceeds from the December 2021 Notes was used to extinguish
$120.0 million
of the February 2018 Notes.
Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require the Company to repurchase their December 2021 Notes at a purchase price equal to 100% of the principal, plus accrued interest.
The December 2021 Notes are convertible under any of the following circumstances:
|
|
•
|
During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ending March 31, 2017, if the last reported sale price of Company common stock for at least
20
trading days (whether or not consecutive), in the period of
30
consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds
130%
of the conversion price for the notes on each applicable trading day;
|
|
|
•
|
During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per
$1,000
principal amount of notes for each trading day of that measurement period was less than
98%
of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; or
|
|
|
•
|
Upon the occurrence of specified corporate events as described in the indenture.
|
The initial conversion rate for the December 2021 Notes is
262.2951
shares of the Company’s common stock per
$1,000
principal amount of December 2021 Notes, which is equivalent to an initial conversion price of approximately
$3.81
per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the indenture.
In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the December 2021 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of
9.5%
, which represents the estimated market interest rate for a similar nonconvertible instrument available to us on the date of issuance, the Company recorded a total debt discount of
$4.3 million
, allocated
$23.8 million
to additional paid-in capital and allocated
$12.8 million
to deferred tax liability. The discount is being amortized to interest expense over the term of the December 2021 Notes and increases interest expense during the term of the December 2021 Notes from the
2.75%
cash coupon interest rate to an effective interest rate of
3.4%
. As of
March 31, 2017
, the remaining discount amortization period is
4.7 years
.
The carrying value and unamortized discount of the December 2021 Notes were as follows:
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
March 31, 2017
|
|
December 31, 2016
|
Principal amount of the December 2021 Notes
|
|
$
|
150,000
|
|
|
$
|
150,000
|
|
Unamortized discount of liability component
|
|
(37,574
|
)
|
|
(39,152
|
)
|
Net carrying value of the December 2021 Notes
|
|
$
|
112,426
|
|
|
$
|
110,848
|
|
Interest expense for the December 2021 Notes on the Company’s Condensed Consolidated Statements of Income was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
March 31,
|
(In thousands)
|
|
2017
|
|
2016
|
Contractual coupon interest
|
|
$
|
1,031
|
|
|
$
|
—
|
|
Amortization of debt issuance costs
|
|
18
|
|
|
—
|
|
Amortization of debt discount
|
|
130
|
|
|
—
|
|
Amortization of conversion feature
|
|
1,430
|
|
|
—
|
|
Total
|
|
$
|
2,609
|
|
|
$
|
—
|
|
As of
March 31, 2017
, the December 2021 Notes are not convertible. At
March 31, 2017
, the if-converted value of the December 2021 Notes did not exceed the principal amount.
Capped Call Transaction
In connection with the offering of the December 2021 Notes, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance. The aggregate cost of the capped call transaction was
$14.4 million
. The capped call transaction is generally expected to reduce the potential dilution upon conversion of the December 2021 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2021 Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction. This initially corresponds to the approximate
$3.81
per share conversion price of the December 2021 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2021 Notes. The cap price of the capped call transaction was initially
$4.88
per share, and is subject to certain adjustments under the terms of the capped call transaction. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company’s common stock, based on the settlement method election chosen for the related convertible notes, with a value equal to the amount by which the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company’s common stock and/or amount of cash subject to the cap price.
The Company evaluated the capped call transaction under authoritative accounting guidance and determined that they should be accounted for as separate transactions and classified as a net reduction to additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded.
March 2015 Term Loan
On March 30, 2015, the Company entered into a credit agreement among the Company, the lenders party thereto and the Royal Bank of Canada, as administrative agent. The credit agreement consisted of a term loan of
$100.0 million
.
The interest rates per annum applicable to amounts outstanding under the term loan were, at the Company’s option, either (a) the alternate base rate (as defined in the credit agreement) plus
0.75%
, or (b) the adjusted Eurodollar rate (as defined in the credit agreement) plus 1.75% per annum. As of February 12, 2016, the interest rate, based upon the adjusted Eurodollar rate, was
2.17%
. Interest payments under the credit agreement were due on the interest payment dates specified in the credit agreement.
The credit agreement required amortization of the term loan in the form of scheduled principal payments on June 15, September 15 and December 15 of 2015, with the remaining outstanding balance due on February 15, 2016. This principal balance and outstanding interest was paid in full on February 12, 2016.
13. Other Long-Term Liabilities
Other long-term liabilities consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
December 31,
|
|
|
2017
|
|
2016
|
(In thousands)
|
|
|
|
|
Accrued lease liability
|
|
$
|
10,700
|
|
|
$
|
10,700
|
|
Long-term incentive accrual
|
|
2,739
|
|
|
1,995
|
|
Uncertain tax positions
|
|
29,973
|
|
|
41,591
|
|
Dividend payable
|
|
149
|
|
|
270
|
|
Total
|
|
$
|
43,561
|
|
|
$
|
54,556
|
|
In connection with the Spin-Off, the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify the Company for all matters related to the leases attributable to the period after the Spin-Off date. As of
March 31, 2017
, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately
$53.6 million
. If Facet were to default, the Company could also be responsible for lease-related costs including utilities, property taxes and common area maintenance that may be as much as the actual lease payments. The Company has
recorded a liability of
$10.7 million
on the Company’s Condensed Consolidated Balance Sheets as of
March 31, 2017
, and December 31, 2016, related to this guarantee.
14. Stock-Based Compensation
The Company grants restricted stock awards pursuant to a stockholder approved stock-based incentive plan. This incentive plan is described in further detail in Note 15, Stock-Based Compensation, of Notes to Condensed Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31,
2016
.
The following table summarizes the Company’s restricted stock award activity during the
three months ended March 31, 2017
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock Awards
|
(In thousands except per share amounts)
|
|
Shares Available for Grant
|
|
Number of Shares Outstanding
|
|
Weighted Average Grant-date Fair Value Per Share
|
Balance at December 31, 2016
|
|
3,432
|
|
|
1,472
|
|
|
$
|
3.96
|
|
Granted
|
|
(1,524
|
)
|
|
1,524
|
|
|
$
|
2.06
|
|
Balance at March 31, 2017
|
|
1,908
|
|
|
2,996
|
|
|
$
|
2.99
|
|
15. Income Taxes
Income tax expense for the three months ended
March 31, 2017
and
2016
, was
$6.6 million
and
$33.0 million
, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. The Company’s effective tax rates for the current period differs from the U.S. federal statutory rate of
35%
due primarily to the effect of Subpart F income as result of the product acquisition triggering U.S. tax on the Company’s pro rata share of income earned by Noden as a controlled foreign corporation. The Company intends to indefinitely reinvest all of its undistributed foreign earnings outside of the United States.
The uncertain tax positions increased during the three months ended
March 31, 2017
and
2016
, by
$0.8 million
and
$1.2 million
, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities.
In general, the Company’s income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 1996 forward. In May 2012, the Company received a “no-change” letter from the Internal Revenue Service (“IRS”) upon completion of an examination of the Company’s 2008 federal tax return. The Company is currently under income tax examination in the state of California for the tax years 2009, 2010, 2011 and 2012. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, the Company does not anticipate any material change to the amount of its unrecognized tax benefit over the next 12 months.
16. Stockholders’ Equity
Stock Repurchase Program
On March 1, 2017, the Company’s board of directors authorized the repurchase through March 2018 of issued and outstanding shares of the Company’s common stock having an aggregate value of up to
$30.0 million
pursuant to a share repurchase program. The repurchases under the share repurchase program are made from time to time in the open market or in privately negotiated transactions and are funded from the Company’s working capital. The amount and timing of such repurchases are dependent upon the price and availability of shares, general market conditions and the availability of cash. Repurchases may also be made under a trading plan under Rule 10b-5, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. The repurchase program may be suspended or discontinued at any time without notice. All shares of common stock repurchased under the Company’s share repurchase program will be retired and restored to authorized but unissued shares of common stock. The Company repurchased
3.9 million
shares of its common stock under the share repurchase program during the period ended March 31, 2017 for an aggregate purchase price of
$8.5 million
, or an average cost of
$2.16
per share. As of March 31, 2017, the Company had
590,000
shares held in treasury stock at total cost of
$1.3 million
. Those shares were settled and retired on April 4, 2017.
17. Business Combinations
Description of the Noden Transaction
On July 1, 2016, Noden Pharma DAC, entered into an asset purchase agreement (“Noden Purchase Agreement”) where by it purchased from Novartis the exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world (collectively the “Noden Products”) and certain related assets and assumed certain related liabilities (the “Noden Transaction”). In addition, pursuant the terms of the Noden Purchase Agreement, Noden Pharma DAC is committed to pay Novartis the following amounts in cash:
$89.0 million
payable on the first anniversary of the closing date, and up to an additional
$95.0 million
contingent on achievement of sales targets and the date of the launch of a generic drug containing the pharmaceutical ingredient aliskiren.
On July 1, 2016, upon the consummation of the Noden Transaction, a noncontrolling interest holder acquired a
6%
equity interest in Noden Pharma DAC and Noden Pharma USA Inc. (together, with any subsidiaries, “Noden”). The equity interest of the noncontrolling interest holder is subject to vesting and repurchase rights over a four-year period. At
March 31, 2017
,
80%
of the noncontrolling interest was subject to repurchase. The Company determined that Noden shall be consolidated under the voting interest model as of
March 31, 2017
.
Pursuant to the Noden Stockholders’ Agreements, the Company expects to make the following additional equity contributions to Noden:
$32.0 million
(and up to
$89.0 million
if Noden is unable to obtain debt financing) on July 1, 2017 to fund the anniversary payment under the Noden Purchase Agreement and at least
$38.0 million
to fund a portion of certain milestone payments under the Noden Purchase Agreement, subject to the occurrence of such milestones.
In connection with the Noden Transaction, Noden Pharma DAC and Novartis also entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden a finished form of the Noden Products and bulk drug form of the Noden Products for specified periods of time prior to the transfer of manufacturing responsibilities for the Noden Products to another manufacturer. Under the supply agreement, Novartis is also obligated to sell the Noden Products on a country-by-country basis during a specified time period prior to Noden Pharma DAC’s assumption of responsibility for sales of Noden Product in such country, and to share profits from such sales with Noden Pharma DAC on a specified basis. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. The supply agreement and Noden Purchase Agreement include other transitional activities to be performed by Novartis, the purpose of which is to effect a smooth transfer of the marketing authorizations necessary to complete the ownership transfer to Noden Pharma DAC.
Fair Value of Consideration Transferred
The preliminary fair value of consideration transferred totals
$244.3 million
, which consists of
$216.7 million
in acquired product rights,
$23.9 million
in customer relationships,
$47.4 million
in contingent consideration and
$87.0 million
in anniversary payments. Contingent consideration includes the future payments that the Company may pay to Novartis based on achieving certain milestones.
The contingent consideration was measured at fair value and will be recognized as of the acquisition date. The Company determined the acquisition date fair value of the contingent consideration obligation based on an income approach derived from the Noden Products revenue estimates and a probability assessment with respect to the likelihood of achieving (a) the level of net sales or (b) generic product launch that would trigger the milestone payments. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The key assumptions in determining the fair value are the discount rate and the probability assigned to the potential milestones being achieved. At each reporting date, the Company will re-measure the contingent consideration obligation to estimated fair value. Any changes in the fair value of contingent consideration will be recognized in operating expenses until the contingent consideration arrangement is settled.
As of the effective time of the acquisition, the identifiable intangible assets are required to be measured at fair value and these assets could include assets that are not intended to be used or sold or that are intended to be used in a manner other than their highest and best use. For purposes of the valuation, it is assumed that all assets will be used in the manner that represents the highest and best use of those assets, but it is not assumed that any market synergies will be achieved. The consideration of synergies has been excluded because they are not considered to be factually supportable.
The fair value of identifiable assets is determined primarily using the “income method,” which starts with a forecast of all expected future cash flows. Some of the more significant assumptions inherent in the development of intangible asset values, from the perspective of a market participant, include, among other factors: the amount and timing of projected future cash flows (including net revenue, cost of product sales, research and development costs, sales and marketing expenses, income tax expense, capital expenditures and working capital requirements) and estimated contributory asset charges; the discount rate selected to measure the risks inherent in the future cash flows; and the assessment of the asset’s life cycle and the competitive trends impacting the asset.
Goodwill represents expected synergies resulting from other intangible assets that do not qualify for separate recognition. Goodwill is calculated as the difference between the acquisition date fair value of the consideration expected to be transferred and the values assigned to the assets acquired. Goodwill is not amortized but tested for impairment on an annual basis or when indications for impairment exist.
The following table presents a summary of the total fair value of consideration transferred for the Noden Products acquisition (in thousands):
|
|
|
|
|
|
Consideration paid in cash at closing
|
|
$
|
109,938
|
|
Discounted anniversary payment
|
|
87,007
|
|
Fair value of contingent consideration
|
|
47,360
|
|
Total fair value of consideration transferred
|
|
$
|
244,305
|
|
Assets Acquired and Liabilities Assumed
In accordance with the authoritative guidance for business combinations, the Noden Transaction was determined to be a business combination and is expected to be accounted for using the acquisition method of accounting. Due to the timing of the Noden Transaction, certain amounts are provisional and subject to change. The provisional amounts consist primarily of the estimates of the fair value of intangible assets acquired and contingent consideration. The Company will finalize these amounts as we obtain the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in adjustments to the provisional amounts recognized at the acquisition date. These changes could be significant. The Company will finalize these amounts no later than one year from the closing date.
The following table summarizes the fair values of the identifiable intangible assets acquired and liabilities assumed at the acquisition date (in thousands):
|
|
|
|
|
|
Acquired product rights
|
|
$
|
216,690
|
|
Customer relationships
|
|
23,880
|
|
Goodwill
|
|
3,735
|
|
Net intangible assets
|
|
$
|
244,305
|
|
The acquired product rights represent developed technology of products approved for sales in the market, which we refer to as marketed products, and have finite useful lives. They are amortized on a straight line basis over a weighted average of 10.0 years. These estimates will be adjusted accordingly if the final identifiable intangible asset valuation generates results, including corresponding useful lives and related amortization methods, which differ from the preliminary estimates, or if the above scope of intangible assets is modified.
Pro Forma Impact of Business Combination
The following table represents the unaudited consolidated financial information for the Company on a pro forma basis for the three months ended March 31, 2017 and 2016, assuming that the Noden Transaction had closed on January 1, 2015. The historical financial information has been adjusted to give effect to pro forma items that are directly attributable to the acquisition and are expected to have a continuing impact on the consolidated results. Additionally, the following table sets forth unaudited financial information and has been compiled from historical financial statements and other information, but is not necessarily indicative of the results that actually would have been achieved had the transactions occurred on the dates indicated or that may be achieved in the future.
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
March 31,
|
|
|
2017
|
|
2016
|
(in thousands)
|
|
|
|
|
Pro forma revenues
|
|
$
|
45,440
|
|
|
$
|
138,847
|
|
Pro forma net income
|
|
$
|
7,241
|
|
|
$
|
61,393
|
|
Pro forma net income per share - basic
|
|
$
|
0.04
|
|
|
$
|
0.38
|
|
Pro forma net income per share - diluted
|
|
$
|
0.04
|
|
|
$
|
0.37
|
|
The unaudited pro forma consolidated results include historical revenues and expenses of assets acquired in the Noden Transaction with the following adjustments:
|
|
•
|
Adjustment to recognize incremental amortization expense based on the fair value of intangibles acquired;
|
|
|
•
|
Eliminate transaction costs and non-recurring charges directly related to the acquisition that were included in the historical results of operations for the Company; and
|
|
|
•
|
Adjustment to recognize pro forma income tax based on income tax benefit on the amortization of intangible asset at the statutory tax rate of Ireland (
12.5%
), and the income tax benefit on the interest expense at the statutory tax rate of the United States (
35.0%
).
|
18. Segment Information
Information regarding the Company’s segments for the three months ended March 31, 2017 and 2016 is as follows:
|
|
|
|
|
|
|
|
|
|
Revenues by segment
|
|
Three Months Ended
|
|
|
March 31,
|
(in thousands)
|
|
2017
|
|
2016
|
Income generating assets
|
|
$
|
32,859
|
|
|
$
|
103,124
|
|
Product sales
|
|
12,581
|
|
|
—
|
|
Total revenues
|
|
$
|
45,440
|
|
|
$
|
103,124
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) by segment
|
|
Three Months Ended
|
|
|
March 31,
|
(in thousands)
|
|
2017
|
|
2016
|
Income generating assets
|
|
$
|
10,974
|
|
|
$
|
55,887
|
|
Product sales
|
|
(3,733
|
)
|
|
—
|
|
Total net income
|
|
$
|
7,241
|
|
|
$
|
55,887
|
|
19. Subsequent Events
Merck Litigation Settlement
On April 21, 2017, the Company entered into a settlement agreement with Merck to resolve the patent infringement lawsuit between the parties pending in the U.S. District Court for the District of New Jersey related to Merck’s Keytruda humanized antibody product. For a further discussion of the settlement with Merck, see Note 11.
Office Lease Extension
On April 24, 2017, the Company extended its Incline Village, NV, office lease for an additional
36 months
at approximately
$14,500
per month. The office lease commitments associated with the extended office lease total approximately $0.5 million over the next 3 years.
Resignation of Noden’s CEO
Elie Farah resigned as chief executive officer and Director of Noden on April 20, 2017. The Company is in process to re-acquire Mr. Farah’s equity interests in Noden.
Share Repurchase Program
From April 1, 2017 to April 28, 2017, the Company repurchased approximately
3.7 million
shares of its common stock under the share repurchase program at a weighted average price of
$2.16
per share for a total of
$7.9 million
. Since the inception of the share repurchase program in March 2017, the Company has repurchased approximately
7.6 million
shares of its common stock for a total of
$16.4 million
.